<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">PLoS One</journal-id><journal-id journal-id-type="iso-abbrev">PLoS ONE</journal-id><journal-id journal-id-type="publisher-id">plos</journal-id><journal-id journal-id-type="pmc">plosone</journal-id><journal-title-group><journal-title>PLoS ONE</journal-title></journal-title-group><issn pub-type="epub">1932-6203</issn><publisher><publisher-name>Public Library of Science</publisher-name><publisher-loc>San Francisco, CA USA</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">31923246</article-id><article-id pub-id-type="pmc">6953848</article-id><article-id pub-id-type="doi">10.1371/journal.pone.0227571</article-id><article-id pub-id-type="publisher-id">PONE-D-19-23376</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Surgical and Invasive Medical Procedures</subject><subj-group><subject>Cardiovascular Procedures</subject><subj-group><subject>Coronary Stenting</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Surgical and Invasive Medical Procedures</subject><subj-group><subject>Stent Implantation</subject><subj-group><subject>Coronary Stenting</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Diagnostic Medicine</subject><subj-group><subject>Signs and Symptoms</subject><subj-group><subject>Hemorrhage</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Pathology and Laboratory Medicine</subject><subj-group><subject>Signs and Symptoms</subject><subj-group><subject>Hemorrhage</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Vascular Medicine</subject><subj-group><subject>Hemorrhage</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Population Biology</subject><subj-group><subject>Population Metrics</subject><subj-group><subject>Death Rates</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Pharmaceutics</subject><subj-group><subject>Drug Therapy</subject><subj-group><subject>Cardiovascular Therapy</subject><subj-group><subject>Anticoagulant Therapy</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Cardiology</subject><subj-group><subject>Myocardial Infarction</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Cardiology</subject><subj-group><subject>Arrhythmia</subject><subj-group><subject>Atrial Fibrillation</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Surgical and Invasive Medical Procedures</subject><subj-group><subject>Stent Implantation</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Surgical and Invasive Medical Procedures</subject><subj-group><subject>Cardiovascular Procedures</subject><subj-group><subject>Revascularization</subject></subj-group></subj-group></subj-group></subj-group></article-categories><title-group><article-title>Drug-eluting versus bare-metal stents for first myocardial infarction in patients with atrial fibrillation: A nationwide population-based cohort study</article-title><alt-title alt-title-type="running-head">Drug-eluting or bare-metal stent for acute myocardial infarction in atrial fibrillation patients</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Chang</surname><given-names>Nen-Chung</given-names></name><role content-type="http://credit.casrai.org/">Conceptualization</role><role content-type="http://credit.casrai.org/">Funding acquisition</role><role content-type="http://credit.casrai.org/">Methodology</role><role content-type="http://credit.casrai.org/">Validation</role><role content-type="http://credit.casrai.org/">Writing &#x02013; original draft</role><xref ref-type="aff" rid="aff001"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Hu</surname><given-names>Patrick</given-names></name><role content-type="http://credit.casrai.org/">Investigation</role><xref ref-type="aff" rid="aff002"><sup>2</sup></xref><xref ref-type="aff" rid="aff003"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Chen</surname><given-names>Tien-Hsing</given-names></name><role content-type="http://credit.casrai.org/">Data curation</role><role content-type="http://credit.casrai.org/">Software</role><role content-type="http://credit.casrai.org/">Supervision</role><role content-type="http://credit.casrai.org/">Validation</role><xref ref-type="aff" rid="aff004"><sup>4</sup></xref></contrib><contrib contrib-type="author"><name><surname>Mao</surname><given-names>Chun-Tai</given-names></name><role content-type="http://credit.casrai.org/">Supervision</role><role content-type="http://credit.casrai.org/">Validation</role><xref ref-type="aff" rid="aff004"><sup>4</sup></xref></contrib><contrib contrib-type="author"><name><surname>Hung</surname><given-names>Ming-Jui</given-names></name><role content-type="http://credit.casrai.org/">Supervision</role><role content-type="http://credit.casrai.org/">Validation</role><xref ref-type="aff" rid="aff004"><sup>4</sup></xref></contrib><contrib contrib-type="author"><name><surname>Yeh</surname><given-names>Chi-Tai</given-names></name><role content-type="http://credit.casrai.org/">Investigation</role><role content-type="http://credit.casrai.org/">Project administration</role><xref ref-type="aff" rid="aff005"><sup>5</sup></xref><xref ref-type="aff" rid="aff006"><sup>6</sup></xref></contrib><contrib contrib-type="author"><contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0002-6912-7523</contrib-id><name><surname>Hung</surname><given-names>Ming-Yow</given-names></name><role content-type="http://credit.casrai.org/">Conceptualization</role><role content-type="http://credit.casrai.org/">Formal analysis</role><role content-type="http://credit.casrai.org/">Funding acquisition</role><role content-type="http://credit.casrai.org/">Methodology</role><role content-type="http://credit.casrai.org/">Project administration</role><role content-type="http://credit.casrai.org/">Resources</role><role content-type="http://credit.casrai.org/">Software</role><role content-type="http://credit.casrai.org/">Validation</role><role content-type="http://credit.casrai.org/">Visualization</role><role content-type="http://credit.casrai.org/">Writing &#x02013; original draft</role><role content-type="http://credit.casrai.org/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="aff" rid="aff007"><sup>7</sup></xref><xref ref-type="aff" rid="aff008"><sup>8</sup></xref><xref ref-type="corresp" rid="cor001">*</xref></contrib></contrib-group><aff id="aff001"><label>1</label>
<addr-line>Division of Cardiology, Department of Internal Medicine, Taipei Medical University Hospital, Taipei, Taiwan</addr-line></aff><aff id="aff002"><label>2</label>
<addr-line>University of California, Riverside, Riverside, California, United States of America</addr-line></aff><aff id="aff003"><label>3</label>
<addr-line>Department of Cardiology, Riverside Medical Clinic, Riverside, California, United States of America</addr-line></aff><aff id="aff004"><label>4</label>
<addr-line>Division of Cardiology, Department of Medicine and Community Medicine Research Center, Chang Gung Memorial Hospital, Keelung, Chang Gung University College of Medicine, Keelung City, Taiwan</addr-line></aff><aff id="aff005"><label>5</label>
<addr-line>Department of Medical Research and Education, Shuang Ho Hospital, Taipei Medical University, New Taipei City, Taiwan</addr-line></aff><aff id="aff006"><label>6</label>
<addr-line>Department of Medical Laboratory Science and Biotechnology, Yuanpei University of Medical Technology, Hsinchu City, Taiwan</addr-line></aff><aff id="aff007"><label>7</label>
<addr-line>Division of Cardiology, Department of Internal Medicine, Shuang Ho Hospital, Taipei Medical University, New Taipei City, Taiwan</addr-line></aff><aff id="aff008"><label>8</label>
<addr-line>Department of Internal Medicine, School of Medicine, College of Medicine, Taipei Medical University, Taipei City, Taiwan</addr-line></aff><contrib-group><contrib contrib-type="editor"><name><surname>Coppola</surname><given-names>Giuseppe</given-names></name><role>Editor</role><xref ref-type="aff" rid="edit1"/></contrib></contrib-group><aff id="edit1"><addr-line>University Hospital *Paolo Giaccone*, ITALY</addr-line></aff><author-notes><fn fn-type="COI-statement" id="coi001"><p><bold>Competing Interests: </bold>The authors have declared that no competing interests exist.</p></fn><corresp id="cor001">* E-mail: <email>myhung6@ms77.hinet.net</email></corresp></author-notes><pub-date pub-type="epub"><day>10</day><month>1</month><year>2020</year></pub-date><pub-date pub-type="collection"><year>2020</year></pub-date><volume>15</volume><issue>1</issue><elocation-id>e0227571</elocation-id><history><date date-type="received"><day>24</day><month>9</month><year>2019</year></date><date date-type="accepted"><day>21</day><month>12</month><year>2019</year></date></history><permissions><copyright-statement>&#x000a9; 2020 Chang et al</copyright-statement><copyright-year>2020</copyright-year><copyright-holder>Chang et al</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="pone.0227571.pdf"/><abstract><sec id="sec001"><title>Background</title><p>Acute myocardial infarction (AMI) complicates the clinical management of atrial fibrillation (AF) because coronary stenting may influence subsequent antithrombotic therapy. We investigated the use of a bare-metal stent (BMS) or a drug-eluting stent (DES) and associated outcomes in patients with pre-existing AF and first AMI undergoing percutaneous coronary intervention.</p></sec><sec id="sec002"><title>Methods and results</title><p>Patient records in this population-based study were retrospectively collected from the Taiwan National Health Insurance Research Database. Using propensity score matching (PSM), we used 1:2 ratio stratification into a DES group of 436 and a BMS group of 785 patients from 2007 to 2011. The mean follow-up of matched cohorts was 1.7 years. After PSM, DESs were associated with lower rates of cardiovascular death (7.8%, hazard ratio [HR] 0.58, 95% confidence interval [CI] 0.39&#x02013;0.86 and 10.1%, HR 0.64, 95% CI 0.45&#x02013;0.90) and primary composite outcome (35.1%, HR 0.76, 95% CI 0.63&#x02013;0.92 and 48.2%, HR 0.81, 95% CI 0.69&#x02013;0.96) than BMSs within the first year and at the end of follow-up. Although the greatest benefit from DESs, irrespective of the first- and second- generation DESs, implantation was observed within the first year only, this benefit was not observed in patients with diabetes, chronic kidney disease, or dialysis.</p></sec><sec id="sec003"><title>Conclusions</title><p>Use of DESs in AMI patients with pre-existing AF is associated with significantly lower rates of cardiovascular death and primary composite outcome within the first year follow-up. However, the effect is not apparent in patients with diabetes, chronic kidney disease or dialysis.</p></sec></abstract><funding-group><award-group id="award001"><funding-source><institution>National Science Council of Taiwan</institution></funding-source><award-id>MOST-108-2314-B-038-119-MY3</award-id><principal-award-recipient><contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0002-6912-7523</contrib-id><name><surname>Hung</surname><given-names>Ming-Yow</given-names></name></principal-award-recipient></award-group><award-group id="award002"><funding-source><institution>Taipei Medical University&#x02013;Shuang Ho Hospital</institution></funding-source><award-id>106TMU-SHH-06</award-id><principal-award-recipient><contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0002-6912-7523</contrib-id><name><surname>Hung</surname><given-names>Ming-Yow</given-names></name></principal-award-recipient></award-group><funding-statement>This work was supported by National Science Council of Taiwan grant to Ming-Yow Hung (MOST-108-2314-B-038-119-MY3); and Taipei Medical University&#x02013;Shuang Ho Hospital (106TMU-SHH-06) to Ming-Yow Hung. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</funding-statement></funding-group><counts><fig-count count="4"/><table-count count="3"/><page-count count="18"/></counts><custom-meta-group><custom-meta id="data-availability"><meta-name>Data Availability</meta-name><meta-value>The dataset used in this study is held by the Taiwan Ministry of Health and Welfare (MOHW). The Ministry of Health and Welfare must approve an application to access this data. Any researcher interested in accessing this dataset can submit an application form to the Ministry of Health and Welfare requesting access. Please contact the staff of MOHW (Email:<email>stcarolwu@mohw.gov.tw</email>) for further assistance. Taiwan Ministry of Health and Welfare Address: No.488, Sec. 6, Zhongxiao E. Rd., Nangang Dist., Taipei City 115, Taiwan (R.O.C.). Phone: +886-2-8590-6848.</meta-value></custom-meta></custom-meta-group></article-meta><notes><title>Data Availability</title><p>The dataset used in this study is held by the Taiwan Ministry of Health and Welfare (MOHW). The Ministry of Health and Welfare must approve an application to access this data. Any researcher interested in accessing this dataset can submit an application form to the Ministry of Health and Welfare requesting access. Please contact the staff of MOHW (Email:<email>stcarolwu@mohw.gov.tw</email>) for further assistance. Taiwan Ministry of Health and Welfare Address: No.488, Sec. 6, Zhongxiao E. Rd., Nangang Dist., Taipei City 115, Taiwan (R.O.C.). Phone: +886-2-8590-6848.</p></notes></front><body><sec sec-type="intro" id="sec004"><title>Introduction</title><p>Atrial fibrillation (AF), the most common sustained arrhythmia, is an independent predictor of acute myocardial infarction (AMI) [<xref rid="pone.0227571.ref001" ref-type="bibr">1</xref>]. While 9.3% of acute coronary syndrome patients have a history of AF [<xref rid="pone.0227571.ref002" ref-type="bibr">2</xref>], the annual rate of AMI in patients with pre-existing AF (AF patients) ranges from 0.4% to 2.5% [<xref rid="pone.0227571.ref003" ref-type="bibr">3</xref>]. Furthermore, a lower annual AMI rate has been described in Asian people (0.2&#x02013;0.3%) [<xref rid="pone.0227571.ref004" ref-type="bibr">4</xref>], suggesting racial heterogeneity in the development of AF-related AMI and underscoring the importance of evaluating the racial differences in associated outcomes. In patients with coronary artery disease undergoing percutaneous coronary intervention (PCI) and stent implantation, the intracoronary and systemic prothrombotic environment accompanying an acute coronary syndrome rather than stable angina has led to concerns regarding a possible higher risk of stent thrombosis [<xref rid="pone.0227571.ref005" ref-type="bibr">5</xref>].</p><p>Consequently, the controversial role of drug-eluting stent (DES) during PCI for MI [<xref rid="pone.0227571.ref006" ref-type="bibr">6</xref>] and the lower use of DES than bare-metal stent (BMS) in AMI patients reflects contemporary clinical practice. On the other hand, in elderly patients with AF undergoing PCI, the use of triple therapy, including dual-antiplatelet therapy (DAPT) and an oral anticoagulant, compared to DAPT alone was associated with reduced thromboembolism and mortality rates, although a higher rate of major bleeding [<xref rid="pone.0227571.ref007" ref-type="bibr">7</xref>]. While the bleeding risk of AF patients is increased due to triple therapy, the most appropriate strategy to balance thrombotic complications after PCI for AF patients requiring coronary stent implantation, are unclear. In the United States, authors of 2006 AF guidelines suggest that the most important agent for the maintenance of stent patency is the thienopyridine derivative clopidogrel and that the addition of aspirin to the chronic anticoagulant regimen contributes more risk than benefit [<xref rid="pone.0227571.ref008" ref-type="bibr">8</xref>]. The use of clopidogrel without aspirin is associated with a reduction in bleeding and no increase in the rate of stent thrombotic events [<xref rid="pone.0227571.ref009" ref-type="bibr">9</xref>]. Moreover, the omission of aspirin while maintaining clopidogrel and oral anticoagulant has been evaluated in the WOEST trial, in which 573 anticoagulated patients undergoing PCI (70% with AF) were randomized to either dual therapy with oral anticoagulant and clopidogrel (75 mg once daily) or to triple therapy with oral anticoagulant, clopidogrel, and aspirin [<xref rid="pone.0227571.ref010" ref-type="bibr">10</xref>, <xref rid="pone.0227571.ref011" ref-type="bibr">11</xref>]. Bleeding was lower in the dual vs. triple therapy arm, driven by fewer minor bleeding events. The rates of myocardial infarction, stroke, target vessel revascularization, and stent thrombosis did not differ (albeit with low event numbers), but all-cause mortality was lower in the dual therapy group at 1 year (2.5% vs. triple therapy 6.4%). Although the trial was too small to assess ischemic outcomes, dual therapy with oral anticoagulant and clopidogrel but without aspirin may emerge in the future as an alternative to triple therapy in patients with AF and ACS and/or PCI [<xref rid="pone.0227571.ref010" ref-type="bibr">10</xref>, <xref rid="pone.0227571.ref012" ref-type="bibr">12</xref>, <xref rid="pone.0227571.ref013" ref-type="bibr">13</xref>]. Similar results of 2 randomized clinical trials, PIONEER AF-PCI and RE-DUAL PCI, support the concept that an oral anticoagulant in combination with single antiplatelet therapy without aspirin, a strategy known as double antithrombotic therapy, is superior to a strategy of triple therapy consisting of the combination of an oral anticoagulant and DAPT in reducing bleeding complications [<xref rid="pone.0227571.ref014" ref-type="bibr">14</xref>&#x02013;<xref rid="pone.0227571.ref016" ref-type="bibr">16</xref>]. On the other hand, the latest 2016 European AF guideline provides recommendations only on antithrombotic therapy strategy, not stent selection [<xref rid="pone.0227571.ref010" ref-type="bibr">10</xref>], which leaves a critical clinical dilemma in the selection of stents when a period of DAPT is also required to minimize the risk of stent thrombosis.</p><p>There is significant heterogeneity in the professional guidance regarding the best type of stent to implant in patients with pre-existing AF. Before 2009, the use of DES in AF patients have not been tested in clinical trials to study the efficacy and safety of these stents, with AF being a common exclusion criterion in clinical trials of DES. In the United States, a class 3 recommendation (harm) appeared in 2013 ST-segment elevation MI guidelines for the use of DESs in patients unable to comply with long-term DAPT [<xref rid="pone.0227571.ref017" ref-type="bibr">17</xref>], which may be a consideration in patients requiring long-term oral anticoagulants. While the first 2011 North American consensus document specifically recommends avoiding DES use in patients with AF and high bleeding risk [<xref rid="pone.0227571.ref018" ref-type="bibr">18</xref>], the use of BMS is considered to minimize the duration of DAPT (class 2b, level of evidence C) in AF guidelines [<xref rid="pone.0227571.ref009" ref-type="bibr">9</xref>, <xref rid="pone.0227571.ref019" ref-type="bibr">19</xref>]. However, in parallel with the advances in antiplatelet therapy, the second 2016 North American consensus document suggests that stents have become safer, with new-generation DES having a lower rate of stent thrombosis than the first-generation DES, and even potentially lower rates than with BMS across manifestations of coronary artery disease, including those with acute ST-segment-elevation MI [<xref rid="pone.0227571.ref020" ref-type="bibr">20</xref>]. In Europe, guidance that is more recent suggests that current-generation DESs may be preferred [<xref rid="pone.0227571.ref021" ref-type="bibr">21</xref>]. However, scarce data are available regarding stent selection and associated outcomes in AF patients presenting with first AMI undergoing PCI. Among AF patients, women are at higher risk of MI than men are, as shown in the REGARDS study [<xref rid="pone.0227571.ref001" ref-type="bibr">1</xref>]. On the other hand, women have smaller coronary arteries and are treated less often with DES than men [<xref rid="pone.0227571.ref022" ref-type="bibr">22</xref>], leading to inferior results following PCI [<xref rid="pone.0227571.ref023" ref-type="bibr">23</xref>]. We, therefore, examined the characteristics of AF patients with a first AMI who received a BMS or a DES, and the effect of BMS versus DES, on interventional outcomes in this nationwide population-based cohort.</p></sec><sec sec-type="materials|methods" id="sec005"><title>Materials and methods</title><sec id="sec006"><title>Data source</title><p>We designed this observational prospective cohort study using the retrospective collected claims data of AF patients presenting with a first episode of AMI from the Taiwan National Health Insurance Research Database (NHIRD) between 2007 and 2011. Disease was detected using the International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) codes in the NHIRD. The NHIRD is generated from the National Health Insurance (NHI) system, a government-operated compulsory health insurance system providing medical care to higher than 99.8% of the 23 million Taiwanese people, and reimburses all the medical expenditures with very few exceptions. The accuracy of all insurance claims was audited under a peer review system conducted by several government-appointed medical specialists. Further information regarding NHI and NHIRD have been described in previous publications [<xref rid="pone.0227571.ref024" ref-type="bibr">24</xref>&#x02013;<xref rid="pone.0227571.ref026" ref-type="bibr">26</xref>].</p></sec><sec id="sec007"><title>Ethics statement</title><p>The encryption system used in the NHIRD makes identifying individuals impossible. Confidentiality is assured by abiding by the Bureau of NHI regulations for data retrieval and use. Therefore, Chang Gung Memorial Hospital Institutional Review Board approval was waived due to the secondary nature of the de-identified data in the retrospective study design. The Chang Gung Memorial Hospital Institutional Review Board specifically waived the consent requirement to access the NHIRD.</p></sec><sec id="sec008"><title>Study population</title><p>This study identified adult patients (&#x02265;20 years) admitted with a first episode of AMI (ICD-9-CM code: 410.xx) from January 1, 2007, to December 31, 2011, from the entire Taiwan population. We chose the first AMI admission as the index hospitalization during the study period when one patient had &#x02265;2 AMI admissions. The positive predictive value of diagnosis codes of AMI was 93% in a previous NHIRD study [<xref rid="pone.0227571.ref027" ref-type="bibr">27</xref>]. We assigned the discharge dates for the first AMI as the index dates. The exclusion criteria were as the follows: prior coronary stent implantation, PCI without stenting during the index hospitalization, or PCI with both BMS and DES during the index hospitalization. The patients were followed from the index date until the date of event occurrence, the date of death or December 31, 2011, whichever came earlier [<xref rid="pone.0227571.ref006" ref-type="bibr">6</xref>, <xref rid="pone.0227571.ref028" ref-type="bibr">28</xref>].</p></sec><sec id="sec009"><title>Exposure</title><p>The exposure of primary interest in this study was the type of stent, namely DES versus BMS, which was used during the index PCI procedure. The type of stent was extracted using Taiwan NHI reimbursement codes in the inpatient claims data. DESs included the first-generation (sirolimus-eluting, paclitaxel-eluting sternts), and the second-generation DESs (everolimus-eluting, zotarolimus-eluting, biolimus-eluting and tacrolimus-eluting stents).</p></sec><sec id="sec010"><title>Covariate</title><p>Covariates were age, sex, monthly income, urbanization level, hospital level of the index AMI hospitalization, 14 comorbidities, 2 previous cardiac interventions (PCI or coronary artery bypass grafting), CHA<sub>2</sub>DS<sub>2</sub>-VASc score, number of intervened diseased vessels, number of stents implanted per patient, in-hospital complications and procedures, 15 kinds of medication at discharge and admission duration. Previous cardiac interventions and in-hospital procedures were retrieved using Taiwan NHI reimbursement codes. The comorbidities were detected using an inpatient diagnosis before the index date, which could be tracked up to year 1997. The ICD-9-CM diagnostic codes of the selected comorbidities were provided in the supplement (<xref ref-type="supplementary-material" rid="pone.0227571.s001">S1 Table</xref>) [<xref rid="pone.0227571.ref028" ref-type="bibr">28</xref>]. The CHA<sub>2</sub>DS<sub>2</sub>-VASc score at the index hospitalization was calculated. We also extracted the prescription records of relevant medications at discharge from the inpatient claims data.</p></sec><sec id="sec011"><title>Outcome</title><p>The primary composite outcome was anyone of ischemic stroke, AMI, revascularization and all-cause mortality. The accuracy of the diagnosis codes for ischemic stroke have been verified in previous NHIRD studies with positive predictive values &#x02265;95% [<xref rid="pone.0227571.ref027" ref-type="bibr">27</xref>, <xref rid="pone.0227571.ref029" ref-type="bibr">29</xref>]. Revascularization by PCI or coronary artery bypass grafting was extracted using the Taiwan NHI reimbursement codes [<xref rid="pone.0227571.ref006" ref-type="bibr">6</xref>]. Due to the obligational and mandatory nature of Taiwan NHI system, a withdrawal from the insurance system was considered a death [<xref rid="pone.0227571.ref030" ref-type="bibr">30</xref>]. We defined cardiovascular death according to the criteria of the Standardized Definitions for Cardiovascular and Stroke Endpoint Events in Clinical Trials by the US Food and Drug Administration [<xref rid="pone.0227571.ref031" ref-type="bibr">31</xref>]. Secondary cardiac and safety outcomes were defined as being admitted with a principal diagnosis of any stroke, hemorrhagic stroke, unspecified stroke, gastrointestinal bleeding, major bleeding and heart failure hospitalization [<xref rid="pone.0227571.ref006" ref-type="bibr">6</xref>, <xref rid="pone.0227571.ref028" ref-type="bibr">28</xref>, <xref rid="pone.0227571.ref032" ref-type="bibr">32</xref>].</p></sec><sec id="sec012"><title>Statistical analysis</title><p>We used propensity score matching to reduce potential confounding effects on the observed variables and selection bias before comparing clinical outcomes between groups (DES versus BMS). The propensity score was the predicted probability to be in the DES group given values of covariates as determined using logistic regression. Selected covariates included 5 demographics (sex, age, monthly income, urbanization level and hospital level), 14 comorbidities, CHA2DS2-VASc score, prior coronary treatment (PCI or coronary artery bypass grafting), angiographic and procedural characteristics, medications administered at discharge, intensive care unit duration, admission durations and the admission date. The matching was processed using a greedy nearest neighbor algorithm with a caliper of 0.2 times of the standard deviation of the logit of the propensity score, with random matching order and without replacement [<xref rid="pone.0227571.ref028" ref-type="bibr">28</xref>]. We matched each patient in the DES group with 2 patients (if possible) in the BMS group.</p><p>Data of categorical and continuous variables are presented as number and percentages and mean &#x000b1; standard deviation, respectively. We compared the baseline characteristics of patients between groups by the chi-square test for categorical variable or by 2-sample <italic>t</italic> test for continuous variable. The risks of time-to-event outcomes between the groups were compared by the Cox proportional hazard model. The study group (DES versus BMS) was the only explanatory variable in the Cox regression. The matched pairs were stratified in the Cox model to account for the outcome dependency within the same matching pair due to matching. We performed a pre-specified subgroup analysis of the primary composite outcome to investigate whether the observed treatment effect on primary composite outcome was consistent across different levels of subgroups. The selected subgroup variables were gender, age, hypertension, diabetes, chronic kidney disease, dialysis, old MI, old stroke, different CHA2DS2-VASc score, shock during admission, acute kidney injury during admission, warfarin, amiodarone, ACEI/ARB, statin and PPIs. Finally, we compared the risks of revascularization, cardiovascular death and primary composite outcome among different stent types (BMS, first- and second- generation DESs) by pairwise log-rank test with Bonferroni adjustment.</p><p>A 2-sided P value &#x0003c;0.05 was considered statistically significant. We made no multiple testing (multiplicity) adjustments in this study. The P value for interaction represents the likelihood of interaction between the variable and the treatment effect (DES versus BMS). We performed all statistical analyses using a commercial software (SAS 9.4, SAS Institute, Cary, NC), including the procedures of &#x02018;psmatch&#x02019; for propensity score matching and &#x02018;phreg&#x02019; for survival analysis.</p></sec></sec><sec sec-type="results" id="sec013"><title>Results</title><sec id="sec014"><title>Patient characteristics</title><p>A total of 88,404 patients firstly admitted with a principal diagnosis of AMI between January 2007 and December 2011 were identified. Among these patients, 8,597 (9.7%) had a history of AF. We further identified 1,971 AF patients who were admitted for first AMI and who subsequently received coronary stenting (<xref ref-type="fig" rid="pone.0227571.g001">Fig 1</xref>). Of those, 1,528 patients (77.5%) underwent BMS implantation and 443 (22.5%) underwent DES implantation. Upon propensity score matching, 349 and 87 DES-treated patients had 2 and 1 counterparts, respectively, resulting in 436 patients in the DES group and 785 patients in the BMS group. The mean follow-up of the matched cohort was 1.7 years (standard deviation = 1.4 years).</p><fig id="pone.0227571.g001" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0227571.g001</object-id><label>Fig 1</label><caption><title>Flow chart for study patient inclusion.</title><p>AF, atrial fibrillation; AMI, acute myocardial infarction; BMS, bare-metal stent; DES, drug-eluting stent; PCI, percutaneous coronary intervention.</p></caption><graphic xlink:href="pone.0227571.g001"/></fig><p>The mean age of patients was 73.2 &#x000b1; 11.5 years and nearly 70% were men. Before propensity score matching was done, DES-treated patients were more likely to live in urbanized area, to receive PCI in a community hospital (not a major medical center), had a lower prevalence of heart failure, chronic obstructive pulmonary disease, stroke, and major bleeding. The DES patients were also more likely to have undergone a prior PCI, had lower CHA2DS2-VASc scores, a higher number of treated vessels, and were less likely to have undergone intra-aortic balloon pump insertion and intubation. They were also less likely to develop cardiogenic shock and receive digoxin and proton-pump inhibitors and were more likely to receive oral hypoglycemic agents, beta-blockers, angiotensin converting enzyme inhibitor/angiotensin II receptor blockers, dihydropyridine calcium channel blockers and statins (P&#x0003c;0.05). After propensity score matching, the baseline characteristics of the 2 groups were well-balanced with insignificant differences in terms of all variables (<xref rid="pone.0227571.t001" ref-type="table">Table 1</xref>).</p><table-wrap id="pone.0227571.t001" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0227571.t001</object-id><label>Table 1</label><caption><title>Baseline characteristics of patients before and after propensity score matching.</title></caption><alternatives><graphic id="pone.0227571.t001g" xlink:href="pone.0227571.t001"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1"/><th align="center" colspan="3" rowspan="1">Before matching</th><th align="center" colspan="3" rowspan="1">After matching</th></tr><tr><th align="left" rowspan="1" colspan="1">Characteristics</th><th align="center" rowspan="1" colspan="1">BMS</th><th align="center" rowspan="1" colspan="1">DES</th><th align="center" rowspan="1" colspan="1">P</th><th align="center" rowspan="1" colspan="1">BMS</th><th align="center" rowspan="1" colspan="1">DES</th><th align="center" rowspan="1" colspan="1">P</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Patient number</td><td align="center" rowspan="1" colspan="1">1,528</td><td align="center" rowspan="1" colspan="1">443</td><td align="center" rowspan="1" colspan="1">&#x02014;</td><td align="center" rowspan="1" colspan="1">785</td><td align="center" rowspan="1" colspan="1">436</td><td align="center" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="left" rowspan="1" colspan="1">Age (year)</td><td align="center" rowspan="1" colspan="1">73.5 &#x000b1; 11.6</td><td align="center" rowspan="1" colspan="1">72.3 &#x000b1; 11.0</td><td align="char" char="." rowspan="1" colspan="1">0.061</td><td align="center" rowspan="1" colspan="1">72.6 &#x000b1; 11.6</td><td align="center" rowspan="1" colspan="1">72.3 &#x000b1; 11.0</td><td align="char" char="." rowspan="1" colspan="1">0.696</td></tr><tr><td align="left" rowspan="1" colspan="1">Age &#x02265;65 years</td><td align="center" rowspan="1" colspan="1">1193 (78.1)</td><td align="center" rowspan="1" colspan="1">342 (77.2)</td><td align="char" char="." rowspan="1" colspan="1">0.696</td><td align="center" rowspan="1" colspan="1">592 (75.4)</td><td align="center" rowspan="1" colspan="1">336 (77.1)</td><td align="char" char="." rowspan="1" colspan="1">0.518</td></tr><tr><td align="left" rowspan="1" colspan="1">Male</td><td align="center" rowspan="1" colspan="1">1,027 (67.2)</td><td align="center" rowspan="1" colspan="1">308 (69.5)</td><td align="char" char="." rowspan="1" colspan="1">0.359</td><td align="center" rowspan="1" colspan="1">545 (69.4)</td><td align="center" rowspan="1" colspan="1">303 (69.5)</td><td align="char" char="." rowspan="1" colspan="1">0.980</td></tr><tr><td align="left" rowspan="1" colspan="1">Monthly income&#x02013;NTD$</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="char" char="." rowspan="1" colspan="1">0.050</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="char" char="." rowspan="1" colspan="1">0.641</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;0</td><td align="center" rowspan="1" colspan="1">500 (32.7)</td><td align="center" rowspan="1" colspan="1">147 (33.2)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">264 (33.6)</td><td align="center" rowspan="1" colspan="1">145 (33.3)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;1&#x02013;20000</td><td align="center" rowspan="1" colspan="1">432 (28.3)</td><td align="center" rowspan="1" colspan="1">101 (22.8)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">198 (25.2)</td><td align="center" rowspan="1" colspan="1">101 (23.2)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x0003e; 20000</td><td align="center" rowspan="1" colspan="1">596 (39.0)</td><td align="center" rowspan="1" colspan="1">195 (44.0)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">323 (41.1)</td><td align="center" rowspan="1" colspan="1">190 (43.6)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Urbanization level</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="char" char="." rowspan="1" colspan="1">&#x0003c;0.001</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="char" char="." rowspan="1" colspan="1">0.675</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;1&#x02013;most urbanized</td><td align="center" rowspan="1" colspan="1">353 (23.1)</td><td align="center" rowspan="1" colspan="1">125 (28.2)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">222 (28.3)</td><td align="center" rowspan="1" colspan="1">123 (28.2)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;2</td><td align="center" rowspan="1" colspan="1">444 (29.1)</td><td align="center" rowspan="1" colspan="1">159 (35.9)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">258 (32.9)</td><td align="center" rowspan="1" colspan="1">155 (35.6)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;3</td><td align="center" rowspan="1" colspan="1">511 (33.4)</td><td align="center" rowspan="1" colspan="1">116 (26.2)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">213 (27.1)</td><td align="center" rowspan="1" colspan="1">115 (26.4)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;4&#x02013;least urbanized</td><td align="center" rowspan="1" colspan="1">220 (14.4)</td><td align="center" rowspan="1" colspan="1">43 (9.7)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">92 (11.7)</td><td align="center" rowspan="1" colspan="1">43 (9.9)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Hospital level</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="char" char="." rowspan="1" colspan="1">&#x0003c;0.001</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="char" char="." rowspan="1" colspan="1">0.372</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Medical center (teaching hospital)</td><td align="center" rowspan="1" colspan="1">821 (53.7)</td><td align="center" rowspan="1" colspan="1">179 (40.4)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">343 (43.7)</td><td align="center" rowspan="1" colspan="1">179 (41.1)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Regional / district hospital</td><td align="center" rowspan="1" colspan="1">707 (46.3)</td><td align="center" rowspan="1" colspan="1">264 (59.6)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">442 (56.3)</td><td align="center" rowspan="1" colspan="1">257 (58.9)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Comorbidities</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Hypertension</td><td align="center" rowspan="1" colspan="1">1,043 (68.3)</td><td align="center" rowspan="1" colspan="1">303 (68.4)</td><td align="char" char="." rowspan="1" colspan="1">0.956</td><td align="center" rowspan="1" colspan="1">546 (69.6)</td><td align="center" rowspan="1" colspan="1">298 (68.3)</td><td align="char" char="." rowspan="1" colspan="1">0.662</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Diabetes mellitus</td><td align="center" rowspan="1" colspan="1">587 (38.4)</td><td align="center" rowspan="1" colspan="1">185 (41.8)</td><td align="char" char="." rowspan="1" colspan="1">0.204</td><td align="center" rowspan="1" colspan="1">318 (40.5)</td><td align="center" rowspan="1" colspan="1">181 (41.5)</td><td align="char" char="." rowspan="1" colspan="1">0.732</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Dyslipidemia</td><td align="center" rowspan="1" colspan="1">395 (25.9)</td><td align="center" rowspan="1" colspan="1">127 (28.7)</td><td align="char" char="." rowspan="1" colspan="1">0.237</td><td align="center" rowspan="1" colspan="1">232 (29.6)</td><td align="center" rowspan="1" colspan="1">125 (28.7)</td><td align="char" char="." rowspan="1" colspan="1">0.745</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Heart failure</td><td align="center" rowspan="1" colspan="1">403 (26.4)</td><td align="center" rowspan="1" colspan="1">84 (19.0)</td><td align="char" char="." rowspan="1" colspan="1">0.001</td><td align="center" rowspan="1" colspan="1">168 (21.4)</td><td align="center" rowspan="1" colspan="1">84 (19.3)</td><td align="char" char="." rowspan="1" colspan="1">0.377</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Chronic kidney disease</td><td align="center" rowspan="1" colspan="1">121 (7.9)</td><td align="center" rowspan="1" colspan="1">25 (5.6)</td><td align="char" char="." rowspan="1" colspan="1">0.107</td><td align="center" rowspan="1" colspan="1">52 (6.6)</td><td align="center" rowspan="1" colspan="1">25 (5.7)</td><td align="char" char="." rowspan="1" colspan="1">0.540</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Dialysis</td><td align="center" rowspan="1" colspan="1">85 (5.6)</td><td align="center" rowspan="1" colspan="1">20 (4.5)</td><td align="char" char="." rowspan="1" colspan="1">0.387</td><td align="center" rowspan="1" colspan="1">45 (5.7)</td><td align="center" rowspan="1" colspan="1">20 (4.6)</td><td align="char" char="." rowspan="1" colspan="1">0.393</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Gout</td><td align="center" rowspan="1" colspan="1">193 (12.6)</td><td align="center" rowspan="1" colspan="1">43 (9.7)</td><td align="char" char="." rowspan="1" colspan="1">0.095</td><td align="center" rowspan="1" colspan="1">75 (9.6)</td><td align="center" rowspan="1" colspan="1">41 (9.4)</td><td align="char" char="." rowspan="1" colspan="1">0.932</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Chronic obstructive pulmonary disease</td><td align="center" rowspan="1" colspan="1">352 (23.0)</td><td align="center" rowspan="1" colspan="1">68 (15.3)</td><td align="char" char="." rowspan="1" colspan="1">0.001</td><td align="center" rowspan="1" colspan="1">133 (16.9)</td><td align="center" rowspan="1" colspan="1">67 (15.4)</td><td align="char" char="." rowspan="1" colspan="1">0.476</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Peripheral arterial disease</td><td align="center" rowspan="1" colspan="1">121 (7.9)</td><td align="center" rowspan="1" colspan="1">31 (7.0)</td><td align="char" char="." rowspan="1" colspan="1">0.522</td><td align="center" rowspan="1" colspan="1">60 (7.6)</td><td align="center" rowspan="1" colspan="1">30 (6.9)</td><td align="char" char="." rowspan="1" colspan="1">0.625</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Malignancy</td><td align="center" rowspan="1" colspan="1">119 (7.8)</td><td align="center" rowspan="1" colspan="1">29 (6.5)</td><td align="char" char="." rowspan="1" colspan="1">0.383</td><td align="center" rowspan="1" colspan="1">48 (6.1)</td><td align="center" rowspan="1" colspan="1">28 (6.4)</td><td align="char" char="." rowspan="1" colspan="1">0.831</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Old myocardial infarction</td><td align="center" rowspan="1" colspan="1">220 (14.4)</td><td align="center" rowspan="1" colspan="1">76 (17.2)</td><td align="char" char="." rowspan="1" colspan="1">0.153</td><td align="center" rowspan="1" colspan="1">133 (16.9)</td><td align="center" rowspan="1" colspan="1">74 (17.0)</td><td align="char" char="." rowspan="1" colspan="1">0.989</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Stroke</td><td align="center" rowspan="1" colspan="1">389 (25.5)</td><td align="center" rowspan="1" colspan="1">87 (19.6)</td><td align="char" char="." rowspan="1" colspan="1">0.012</td><td align="center" rowspan="1" colspan="1">169 (21.5)</td><td align="center" rowspan="1" colspan="1">86 (19.7)</td><td align="char" char="." rowspan="1" colspan="1">0.457</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Gastrointestinal bleeding</td><td align="center" rowspan="1" colspan="1">395 (25.9)</td><td align="center" rowspan="1" colspan="1">95 (21.4)</td><td align="char" char="." rowspan="1" colspan="1">0.059</td><td align="center" rowspan="1" colspan="1">183 (23.3)</td><td align="center" rowspan="1" colspan="1">92 (21.1)</td><td align="char" char="." rowspan="1" colspan="1">0.375</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Major bleeding</td><td align="center" rowspan="1" colspan="1">160 (10.5)</td><td align="center" rowspan="1" colspan="1">31 (7.0)</td><td align="char" char="." rowspan="1" colspan="1">0.030</td><td align="center" rowspan="1" colspan="1">57 (7.3)</td><td align="center" rowspan="1" colspan="1">31 (7.1)</td><td align="char" char="." rowspan="1" colspan="1">0.922</td></tr><tr><td align="left" rowspan="1" colspan="1">Previous treatment</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Percutaneous coronary intervention</td><td align="center" rowspan="1" colspan="1">122 (8.0)</td><td align="center" rowspan="1" colspan="1">54 (12.2)</td><td align="char" char="." rowspan="1" colspan="1">0.006</td><td align="center" rowspan="1" colspan="1">87 (11.1)</td><td align="center" rowspan="1" colspan="1">51 (11.7)</td><td align="char" char="." rowspan="1" colspan="1">0.745</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Coronary artery bypass grafting</td><td align="center" rowspan="1" colspan="1">37 (2.4)</td><td align="center" rowspan="1" colspan="1">12 (2.7)</td><td align="char" char="." rowspan="1" colspan="1">0.732</td><td align="center" rowspan="1" colspan="1">21 (2.7)</td><td align="center" rowspan="1" colspan="1">12 (2.8)</td><td align="char" char="." rowspan="1" colspan="1">0.937</td></tr><tr><td align="left" rowspan="1" colspan="1">CHA<sub>2</sub>DS<sub>2</sub>-VASc score</td><td align="center" rowspan="1" colspan="1">4.0&#x000b1;2.2</td><td align="center" rowspan="1" colspan="1">3.8&#x000b1;2.1</td><td align="char" char="." rowspan="1" colspan="1">0.050</td><td align="center" rowspan="1" colspan="1">3.9&#x000b1;2.1</td><td align="center" rowspan="1" colspan="1">3.8&#x000b1;2.2</td><td align="char" char="." rowspan="1" colspan="1">0.608</td></tr><tr><td align="left" rowspan="1" colspan="1">CHA<sub>2</sub>DS<sub>2</sub>-VASc score group</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="char" char="." rowspan="1" colspan="1">0.037</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="char" char="." rowspan="1" colspan="1">0.987</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;1</td><td align="center" rowspan="1" colspan="1">221 (14.5)</td><td align="center" rowspan="1" colspan="1">64 (14.4)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">111 (14.1)</td><td align="center" rowspan="1" colspan="1">64 (14.7)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;2</td><td align="center" rowspan="1" colspan="1">193 (12.6)</td><td align="center" rowspan="1" colspan="1">65 (14.7)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">119 (15.2)</td><td align="center" rowspan="1" colspan="1">64 (14.7)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;3&#x02013;5</td><td align="center" rowspan="1" colspan="1">688 (45.0)</td><td align="center" rowspan="1" colspan="1">220 (49.7)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">384 (48.9)</td><td align="center" rowspan="1" colspan="1">215 (49.3)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02265; 6</td><td align="center" rowspan="1" colspan="1">426 (27.9)</td><td align="center" rowspan="1" colspan="1">94 (21.2)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">171 (21.8)</td><td align="center" rowspan="1" colspan="1">93 (21.3)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">No. of intervened disease vessels</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="char" char="." rowspan="1" colspan="1">0.003</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="char" char="." rowspan="1" colspan="1">0.487</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;1</td><td align="center" rowspan="1" colspan="1">1,203 (78.7)</td><td align="center" rowspan="1" colspan="1">319 (72.0)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">595 (75.8)</td><td align="center" rowspan="1" colspan="1">317 (72.7)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;2</td><td align="center" rowspan="1" colspan="1">290 (19.0)</td><td align="center" rowspan="1" colspan="1">104 (23.5)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">164 (20.9)</td><td align="center" rowspan="1" colspan="1">102 (23.4)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;3</td><td align="center" rowspan="1" colspan="1">35 (2.3)</td><td align="center" rowspan="1" colspan="1">20 (4.5)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">26 (3.3)</td><td align="center" rowspan="1" colspan="1">17 (3.9)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">No. of stents implanted per patient</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="char" char="." rowspan="1" colspan="1">0.558</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="char" char="." rowspan="1" colspan="1">0.870</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;1</td><td align="center" rowspan="1" colspan="1">1,076 (70.4)</td><td align="center" rowspan="1" colspan="1">324 (73.1)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">579 (73.8)</td><td align="center" rowspan="1" colspan="1">317 (72.7)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;2</td><td align="center" rowspan="1" colspan="1">339 (22.2)</td><td align="center" rowspan="1" colspan="1">89 (20.1)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">155 (19.7)</td><td align="center" rowspan="1" colspan="1">89 (20.4)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;3</td><td align="center" rowspan="1" colspan="1">85 (5.6)</td><td align="center" rowspan="1" colspan="1">25 (5.6)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">39 (5.0)</td><td align="center" rowspan="1" colspan="1">25 (5.7)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;4 or more</td><td align="center" rowspan="1" colspan="1">28 (1.8)</td><td align="center" rowspan="1" colspan="1">5 (1.1)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">12 (1.5)</td><td align="center" rowspan="1" colspan="1">5 (1.1)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Aspiration catheter used</td><td align="center" rowspan="1" colspan="1">216 (14.1)</td><td align="center" rowspan="1" colspan="1">52 (11.7)</td><td align="char" char="." rowspan="1" colspan="1">0.195</td><td align="center" rowspan="1" colspan="1">94 (12.0)</td><td align="center" rowspan="1" colspan="1">52 (11.9)</td><td align="char" char="." rowspan="1" colspan="1">0.980</td></tr><tr><td align="left" rowspan="1" colspan="1">Intra-aortic balloon pump</td><td align="center" rowspan="1" colspan="1">222 (14.5)</td><td align="center" rowspan="1" colspan="1">37 (8.4)</td><td align="char" char="." rowspan="1" colspan="1">0.001</td><td align="center" rowspan="1" colspan="1">73 (9.3)</td><td align="center" rowspan="1" colspan="1">37 (8.5)</td><td align="char" char="." rowspan="1" colspan="1">0.634</td></tr><tr><td align="left" rowspan="1" colspan="1">Intubation</td><td align="center" rowspan="1" colspan="1">264 (17.3)</td><td align="center" rowspan="1" colspan="1">46 (10.4)</td><td align="char" char="." rowspan="1" colspan="1">&#x0003c;0.001</td><td align="center" rowspan="1" colspan="1">88 (11.2)</td><td align="center" rowspan="1" colspan="1">45 (10.3)</td><td align="char" char="." rowspan="1" colspan="1">0.633</td></tr><tr><td align="left" rowspan="1" colspan="1">Extracorporeal membrane oxygenation</td><td align="center" rowspan="1" colspan="1">17 (1.1)</td><td align="center" rowspan="1" colspan="1">6 (1.4)</td><td align="char" char="." rowspan="1" colspan="1">0.676</td><td align="center" rowspan="1" colspan="1">15 (1.9)</td><td align="center" rowspan="1" colspan="1">6 (1.4)</td><td align="char" char="." rowspan="1" colspan="1">0.491</td></tr><tr><td align="left" rowspan="1" colspan="1">Cardiogenic shock with MCS</td><td align="center" rowspan="1" colspan="1">224 (14.7)</td><td align="center" rowspan="1" colspan="1">37 (8.4)</td><td align="char" char="." rowspan="1" colspan="1">0.001</td><td align="center" rowspan="1" colspan="1">75 (9.6)</td><td align="center" rowspan="1" colspan="1">37 (8.5)</td><td align="char" char="." rowspan="1" colspan="1">0.536</td></tr><tr><td align="left" rowspan="1" colspan="1">Acute kidney injury</td><td align="center" rowspan="1" colspan="1">74 (4.8)</td><td align="center" rowspan="1" colspan="1">12 (2.7)</td><td align="char" char="." rowspan="1" colspan="1">0.053</td><td align="center" rowspan="1" colspan="1">30 (3.8)</td><td align="center" rowspan="1" colspan="1">11 (2.5)</td><td align="char" char="." rowspan="1" colspan="1">0.227</td></tr><tr><td align="left" rowspan="1" colspan="1">Stay of intensive care unit (days)</td><td align="center" rowspan="1" colspan="1">5.5 &#x000b1; 8.0</td><td align="center" rowspan="1" colspan="1">4.7 &#x000b1; 8.4</td><td align="char" char="." rowspan="1" colspan="1">0.059</td><td align="center" rowspan="1" colspan="1">4.7 &#x000b1; 7.0</td><td align="center" rowspan="1" colspan="1">4.5 &#x000b1; 7.4</td><td align="char" char="." rowspan="1" colspan="1">0.635</td></tr><tr><td align="left" rowspan="1" colspan="1">Medication at discharge</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Digoxin</td><td align="center" rowspan="1" colspan="1">304 (19.9)</td><td align="center" rowspan="1" colspan="1">64 (14.4)</td><td align="char" char="." rowspan="1" colspan="1">0.010</td><td align="center" rowspan="1" colspan="1">138 (17.6)</td><td align="center" rowspan="1" colspan="1">64 (14.7)</td><td align="char" char="." rowspan="1" colspan="1">0.191</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Warfarin</td><td align="center" rowspan="1" colspan="1">119 (7.8)</td><td align="center" rowspan="1" colspan="1">40 (9.0)</td><td align="char" char="." rowspan="1" colspan="1">0.398</td><td align="center" rowspan="1" colspan="1">64 (8.2)</td><td align="center" rowspan="1" colspan="1">39 (8.9)</td><td align="char" char="." rowspan="1" colspan="1">0.633</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Amiodarone</td><td align="center" rowspan="1" colspan="1">856 (56.0)</td><td align="center" rowspan="1" colspan="1">229 (51.7)</td><td align="char" char="." rowspan="1" colspan="1">0.107</td><td align="center" rowspan="1" colspan="1">412 (52.5)</td><td align="center" rowspan="1" colspan="1">226 (51.8)</td><td align="char" char="." rowspan="1" colspan="1">0.828</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Oral hypoglycemic agent</td><td align="center" rowspan="1" colspan="1">378 (24.7)</td><td align="center" rowspan="1" colspan="1">131 (29.6)</td><td align="char" char="." rowspan="1" colspan="1">0.041</td><td align="center" rowspan="1" colspan="1">226 (28.8)</td><td align="center" rowspan="1" colspan="1">128 (29.4)</td><td align="char" char="." rowspan="1" colspan="1">0.834</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Insulin</td><td align="center" rowspan="1" colspan="1">424 (27.7)</td><td align="center" rowspan="1" colspan="1">110 (24.8)</td><td align="char" char="." rowspan="1" colspan="1">0.224</td><td align="center" rowspan="1" colspan="1">203 (25.9)</td><td align="center" rowspan="1" colspan="1">109 (25.0)</td><td align="char" char="." rowspan="1" colspan="1">0.741</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Aspirin</td><td align="center" rowspan="1" colspan="1">1,422 (93.1)</td><td align="center" rowspan="1" colspan="1">422 (95.3)</td><td align="char" char="." rowspan="1" colspan="1">0.097</td><td align="center" rowspan="1" colspan="1">742 (94.5)</td><td align="center" rowspan="1" colspan="1">415 (95.2)</td><td align="char" char="." rowspan="1" colspan="1">0.619</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Clopidogrel</td><td align="center" rowspan="1" colspan="1">1,510 (98.8)</td><td align="center" rowspan="1" colspan="1">439 (99.1)</td><td align="char" char="." rowspan="1" colspan="1">0.628</td><td align="center" rowspan="1" colspan="1">779 (99.2)</td><td align="center" rowspan="1" colspan="1">432 (99.1)</td><td align="char" char="." rowspan="1" colspan="1">0.776</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Dual antiplatelet</td><td align="center" rowspan="1" colspan="1">1,416 (92.7)</td><td align="center" rowspan="1" colspan="1">420 (94.8)</td><td align="char" char="." rowspan="1" colspan="1">0.117</td><td align="center" rowspan="1" colspan="1">740 (94.3)</td><td align="center" rowspan="1" colspan="1">413 (94.7)</td><td align="char" char="." rowspan="1" colspan="1">0.739</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Beta-blocker</td><td align="center" rowspan="1" colspan="1">916 (59.9)</td><td align="center" rowspan="1" colspan="1">310 (70.0)</td><td align="char" char="." rowspan="1" colspan="1">&#x0003c;0.001</td><td align="center" rowspan="1" colspan="1">546 (69.6)</td><td align="center" rowspan="1" colspan="1">304 (69.7)</td><td align="char" char="." rowspan="1" colspan="1">0.950</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;ACEI / ARB</td><td align="center" rowspan="1" colspan="1">1,108 (72.5)</td><td align="center" rowspan="1" colspan="1">354 (79.9)</td><td align="char" char="." rowspan="1" colspan="1">0.002</td><td align="center" rowspan="1" colspan="1">621 (79.1)</td><td align="center" rowspan="1" colspan="1">348 (79.8)</td><td align="char" char="." rowspan="1" colspan="1">0.770</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;DCCB</td><td align="center" rowspan="1" colspan="1">282 (18.5)</td><td align="center" rowspan="1" colspan="1">110 (24.8)</td><td align="char" char="." rowspan="1" colspan="1">0.003</td><td align="center" rowspan="1" colspan="1">432 (55.0)</td><td align="center" rowspan="1" colspan="1">257 (58.9)</td><td align="char" char="." rowspan="1" colspan="1">0.186</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Statin</td><td align="center" rowspan="1" colspan="1">722 (47.3)</td><td align="center" rowspan="1" colspan="1">260 (58.7)</td><td align="char" char="." rowspan="1" colspan="1">&#x0003c;0.001</td><td align="center" rowspan="1" colspan="1">98 (12.5)</td><td align="center" rowspan="1" colspan="1">50 (11.5)</td><td align="char" char="." rowspan="1" colspan="1">0.602</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Proton-pump inhibitor</td><td align="center" rowspan="1" colspan="1">231 (15.1)</td><td align="center" rowspan="1" colspan="1">50 (11.3)</td><td align="char" char="." rowspan="1" colspan="1">0.042</td><td align="center" rowspan="1" colspan="1">182 (23.2)</td><td align="center" rowspan="1" colspan="1">104 (23.9)</td><td align="char" char="." rowspan="1" colspan="1">0.792</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;NDCCB</td><td align="center" rowspan="1" colspan="1">339 (22.2)</td><td align="center" rowspan="1" colspan="1">86 (19.4)</td><td align="char" char="." rowspan="1" colspan="1">0.211</td><td align="center" rowspan="1" colspan="1">159 (20.3)</td><td align="center" rowspan="1" colspan="1">85 (19.5)</td><td align="char" char="." rowspan="1" colspan="1">0.751</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Glycoprotein IIb/IIIa</td><td align="center" rowspan="1" colspan="1">38 (2.5)</td><td align="center" rowspan="1" colspan="1">9 (2.0)</td><td align="char" char="." rowspan="1" colspan="1">0.580</td><td align="center" rowspan="1" colspan="1">17 (2.2)</td><td align="center" rowspan="1" colspan="1">9 (2.1)</td><td align="char" char="." rowspan="1" colspan="1">0.906</td></tr><tr><td align="left" rowspan="1" colspan="1">Index admission duration (day)</td><td align="center" rowspan="1" colspan="1">11.8 &#x000b1; 15.9</td><td align="center" rowspan="1" colspan="1">10.3 &#x000b1; 13.7</td><td align="char" char="." rowspan="1" colspan="1">0.075</td><td align="center" rowspan="1" colspan="1">10.5 &#x000b1; 12.8</td><td align="center" rowspan="1" colspan="1">10.1 &#x000b1; 12.7</td><td align="char" char="." rowspan="1" colspan="1">0.557</td></tr><tr><td align="left" rowspan="1" colspan="1">Follow up years</td><td align="center" rowspan="1" colspan="1">1.5 &#x000b1; 1.4</td><td align="center" rowspan="1" colspan="1">1.8 &#x000b1; 1.4</td><td align="char" char="." rowspan="1" colspan="1">0.001</td><td align="center" rowspan="1" colspan="1">1.6 &#x000b1; 1.4</td><td align="center" rowspan="1" colspan="1">1.8 &#x000b1; 1.4</td><td align="char" char="." rowspan="1" colspan="1">0.017</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="t001fn001"><p>Values are means &#x000b1; standard deviation, or numbers (percentages).</p></fn><fn id="t001fn002"><p>BMS, bare-metal stent; DES, drug-eluting stent; NTD, New Taiwan dollar; MCS, mechanical circulation support; ACEI, angiotensin converting enzyme inhibitor; ARB, angiotensin II receptor blocker; DCCB, dihydropyridine calcium channel blocker; NDCCB, non-dihydropyridine calcium channel blocker.</p></fn></table-wrap-foot></table-wrap></sec><sec id="sec015"><title>Clinical outcomes</title><p>No significant differences in the risks of ischemic stroke, MI and revascularization during the 1-year follow-up or the end of follow-up were observed. However, the event rate of cardiovascular death during the 1-year follow-up was 7.8% (34/436) and 13.0% (102/785) in the DES and BMS groups, respectively (<xref rid="pone.0227571.t002" ref-type="table">Table 2</xref>). The DES patients had significantly lower risks of cardiovascular death (hazard ratio [HR] 0.58, 95% confidence interval [CI] 0.39&#x02013;0.86) and primary composite outcome (HR 0.76, 95% CI 0.63&#x02013;0.92). Moreover, the event rates of the primary composite outcome during the 1-year follow-up were 35.1% (153/436) and 43.3% (340/785) in the DES and BMS groups, respectively.</p><table-wrap id="pone.0227571.t002" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0227571.t002</object-id><label>Table 2</label><caption><title>Cardiovascular outcomes.</title></caption><alternatives><graphic id="pone.0227571.t002g" xlink:href="pone.0227571.t002"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="left" rowspan="2" colspan="1">Follow up / Outcome</th><th align="center" colspan="2" rowspan="1">Number of event (%)</th><th align="center" rowspan="2" colspan="1">DES versus BMS<break/>HR (95% CI)</th><th align="center" rowspan="2" colspan="1">P</th></tr><tr><th align="center" rowspan="1" colspan="1">BMS<break/>(n = 785)</th><th align="center" rowspan="1" colspan="1">DES<break/>(n = 436)</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">1 year follow up</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Ischemic stroke</td><td align="center" rowspan="1" colspan="1">38 (4.8)</td><td align="center" rowspan="1" colspan="1">25 (5.7)</td><td align="center" rowspan="1" colspan="1">1.10 (0.66&#x02013;1.82)</td><td align="char" char="." rowspan="1" colspan="1">0.716</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Myocardial infarction</td><td align="center" rowspan="1" colspan="1">35 (4.5)</td><td align="center" rowspan="1" colspan="1">19 (4.4)</td><td align="center" rowspan="1" colspan="1">0.91 (0.52&#x02013;1.59)</td><td align="char" char="." rowspan="1" colspan="1">0.745</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Revascularization</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;PCI</td><td align="center" rowspan="1" colspan="1">143 (18.2)</td><td align="center" rowspan="1" colspan="1">73 (16.7)</td><td align="center" rowspan="1" colspan="1">0.84 (0.64&#x02013;1.12)</td><td align="char" char="." rowspan="1" colspan="1">0.235</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;CABG</td><td align="center" rowspan="1" colspan="1">9 (1.1)</td><td align="center" rowspan="1" colspan="1">2 (0.5)</td><td align="center" rowspan="1" colspan="1">0.37 (0.08&#x02013;1.70)</td><td align="char" char="." rowspan="1" colspan="1">0.201</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Death from any cause</td><td align="center" rowspan="1" colspan="1">187 (23.8)</td><td align="center" rowspan="1" colspan="1">67 (15.4)</td><td align="center" rowspan="1" colspan="1">0.61 (0.46&#x02013;0.81)</td><td align="char" char="." rowspan="1" colspan="1">0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Cardiovascular death</td><td align="center" rowspan="1" colspan="1">102 (13.0)</td><td align="center" rowspan="1" colspan="1">34 (7.8)</td><td align="center" rowspan="1" colspan="1">0.58 (0.39&#x02013;0.86)</td><td align="char" char="." rowspan="1" colspan="1">0.006</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Primary composite outcome<xref ref-type="table-fn" rid="t002fn002">*</xref></td><td align="center" rowspan="1" colspan="1">340 (43.3)</td><td align="center" rowspan="1" colspan="1">153 (35.1)</td><td align="center" rowspan="1" colspan="1">0.76 (0.63&#x02013;0.92)</td><td align="char" char="." rowspan="1" colspan="1">0.005</td></tr><tr><td align="left" rowspan="1" colspan="1">At the end of follow-up</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Ischemic stroke</td><td align="center" rowspan="1" colspan="1">58 (7.4)</td><td align="center" rowspan="1" colspan="1">37 (8.5)</td><td align="center" rowspan="1" colspan="1">1.05 (0.69&#x02013;1.58)</td><td align="char" char="." rowspan="1" colspan="1">0.835</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Myocardial infarction</td><td align="center" rowspan="1" colspan="1">43 (5.5)</td><td align="center" rowspan="1" colspan="1">32 (7.3)</td><td align="center" rowspan="1" colspan="1">1.23 (0.78&#x02013;1.94)</td><td align="char" char="." rowspan="1" colspan="1">0.385</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Revascularization</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;PCI</td><td align="center" rowspan="1" colspan="1">178 (22.7)</td><td align="center" rowspan="1" colspan="1">101 (23.2)</td><td align="center" rowspan="1" colspan="1">0.92 (0.72&#x02013;1.17)</td><td align="char" char="." rowspan="1" colspan="1">0.474</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;CABG</td><td align="center" rowspan="1" colspan="1">12 (1.5)</td><td align="center" rowspan="1" colspan="1">4 (0.9)</td><td align="center" rowspan="1" colspan="1">0.54 (0.17&#x02013;1.66)</td><td align="char" char="." rowspan="1" colspan="1">0.279</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Death from any cause</td><td align="center" rowspan="1" colspan="1">251 (32.0)</td><td align="center" rowspan="1" colspan="1">107 (24.5)</td><td align="center" rowspan="1" colspan="1">0.71 (0.57&#x02013;0.89)</td><td align="char" char="." rowspan="1" colspan="1">0.003</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Cardiovascular death</td><td align="center" rowspan="1" colspan="1">118 (15.0)</td><td align="center" rowspan="1" colspan="1">44 (10.1)</td><td align="center" rowspan="1" colspan="1">0.64 (0.45&#x02013;0.90)</td><td align="char" char="." rowspan="1" colspan="1">0.011</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Primary composite outcome<xref ref-type="table-fn" rid="t002fn002">*</xref></td><td align="center" rowspan="1" colspan="1">427 (54.4)</td><td align="center" rowspan="1" colspan="1">210 (48.2)</td><td align="center" rowspan="1" colspan="1">0.81 (0.69&#x02013;0.96)</td><td align="char" char="." rowspan="1" colspan="1">0.015</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="t002fn001"><p>BMS, bare-metal stent; DES, drug-eluting stent; HR, hazard ratio; CI, confidence interval; PCI, percutaneous coronary intervention; CABG, coronary artery bypass graft; CV, cardiovascular.</p></fn><fn id="t002fn002"><p>*Any one of the following: ischemic stroke, myocardial infarction, revascularization, and death from any cause</p></fn></table-wrap-foot></table-wrap><p>At the end of follow-up, the event rate of cardiovascular deaths was 10.1% (44/436) and 15.0% (118/785) in the DES and BMS groups, respectively. The DES patients had significantly lower risks of cardiovascular death (HR 0.64, 95% CI 0.45&#x02013;0.90; <xref ref-type="fig" rid="pone.0227571.g002">Fig 2A</xref>) and primary composite outcome (HR 0.81, 95% CI 0.69&#x02013;0.96; <xref ref-type="fig" rid="pone.0227571.g002">Fig 2C</xref>). The event rates of primary composite outcome were 48.2% (210/436) and 54.4% (427/785) in the DES and BMS groups, respectively (<xref rid="pone.0227571.t002" ref-type="table">Table 2</xref>). Although the benefit from DES implantation was the greatest only during the first year after treatment for first AMI, DES or BMS selection demonstrated insignificant differences of cardiovascular death (<xref ref-type="fig" rid="pone.0227571.g002">Fig 2B</xref>) and primary composite outcome (<xref ref-type="fig" rid="pone.0227571.g002">Fig 2D</xref>) beyond the first year follow-up.</p><fig id="pone.0227571.g002" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0227571.g002</object-id><label>Fig 2</label><caption><title>Cumulative event rate of cardiovascular death and primary composite outcome.</title><p>Cumulative event rate of cardiovascular death (A+B) and primary composite outcome (C+D) at the end of follow-up and stratified by 1-year follow-up. BMS, bare-metal stent; CV, cardiovascular; DES, drug-eluting stent.</p></caption><graphic xlink:href="pone.0227571.g002"/></fig><p>Regarding secondary and safety outcomes, we found no significant differences in the risks of stroke (HR 0.93, 95% CI 0.62&#x02013;1.38), heart failure admission (HR 0.72, 95% CI 0.50&#x02013;1.02), or major bleeding (HR 0.85, 95% CI 0.51&#x02013;1.41) between groups (<xref rid="pone.0227571.t003" ref-type="table">Table 3</xref>).</p><table-wrap id="pone.0227571.t003" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0227571.t003</object-id><label>Table 3</label><caption><title>Secondary outcome at the end of follow-up.</title></caption><alternatives><graphic id="pone.0227571.t003g" xlink:href="pone.0227571.t003"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="left" rowspan="2" colspan="1">Outcome</th><th align="center" colspan="2" rowspan="1">Number of event (%)</th><th align="center" rowspan="2" colspan="1">DES versus BMS<break/>HR (95% CI)</th><th align="center" rowspan="2" colspan="1">P</th></tr><tr><th align="center" rowspan="1" colspan="1">BMS<break/>(n = 785)</th><th align="center" rowspan="1" colspan="1">DES<break/>(n = 436)</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Any stroke</td><td align="center" rowspan="1" colspan="1">67 (8.5)</td><td align="center" rowspan="1" colspan="1">38 (8.7)</td><td align="center" rowspan="1" colspan="1">0.93 (0.62&#x02013;1.38)</td><td align="char" char="." rowspan="1" colspan="1">0.711</td></tr><tr><td align="left" rowspan="1" colspan="1">Hemorrhagic stroke</td><td align="center" rowspan="1" colspan="1">7 (0.9)</td><td align="center" rowspan="1" colspan="1">2 (0.5)</td><td align="center" rowspan="1" colspan="1">0.46 (0.10&#x02013;2.22)</td><td align="char" char="." rowspan="1" colspan="1">0.334</td></tr><tr><td align="left" rowspan="1" colspan="1">Unspecified stroke</td><td align="center" rowspan="1" colspan="1">7 (0.9)</td><td align="center" rowspan="1" colspan="1">2 (0.5)</td><td align="center" rowspan="1" colspan="1">0.46 (0.10&#x02013;2.21)</td><td align="char" char="." rowspan="1" colspan="1">0.332</td></tr><tr><td align="left" rowspan="1" colspan="1">Gastrointestinal bleeding</td><td align="center" rowspan="1" colspan="1">87 (11.1)</td><td align="center" rowspan="1" colspan="1">40 (9.2)</td><td align="center" rowspan="1" colspan="1">0.74 (0.51&#x02013;1.07)</td><td align="char" char="." rowspan="1" colspan="1">0.107</td></tr><tr><td align="left" rowspan="1" colspan="1">Major bleeding</td><td align="center" rowspan="1" colspan="1">44 (5.6)</td><td align="center" rowspan="1" colspan="1">23 (5.3)</td><td align="center" rowspan="1" colspan="1">0.85 (0.51&#x02013;1.41)</td><td align="char" char="." rowspan="1" colspan="1">0.527</td></tr><tr><td align="left" rowspan="1" colspan="1">Major bleeding (include gastrointestinal bleeding)</td><td align="center" rowspan="1" colspan="1">102 (13.0)</td><td align="center" rowspan="1" colspan="1">46 (10.6)</td><td align="center" rowspan="1" colspan="1">0.72 (0.51&#x02013;1.02)</td><td align="char" char="." rowspan="1" colspan="1">0.061</td></tr><tr><td align="left" rowspan="1" colspan="1">Heart failure admission</td><td align="center" rowspan="1" colspan="1">99 (12.6)</td><td align="center" rowspan="1" colspan="1">44 (10.1)</td><td align="center" rowspan="1" colspan="1">0.72 (0.50&#x02013;1.02)</td><td align="char" char="." rowspan="1" colspan="1">0.068</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="t003fn001"><p>BMS, bare-metal stent; DES, drug-eluting stent; HR, hazard ratio; CI, confidence interval.</p></fn></table-wrap-foot></table-wrap></sec><sec id="sec016"><title>Subgroup analyses</title><p>We further analyzed the primary composite outcome at the end of follow-up, stratified by patient&#x02019;s characteristics. The beneficial effect of DES was less apparent in patients with diabetes (P interaction = 0.0501), CKD (<italic>p</italic> interaction = 0.046), or dialysis (P interaction = 0.021) (<xref ref-type="fig" rid="pone.0227571.g003">Fig 3</xref>). Moreover, while no difference was found in the rates of revascularization associated with DES or BMS (<xref ref-type="fig" rid="pone.0227571.g004">Fig 4A</xref>), both the first- and second- generation DESs were associated with significantly lower rates of cardiovascular death (<xref ref-type="fig" rid="pone.0227571.g004">Fig 4B</xref>) and primary composite outcome (<xref ref-type="fig" rid="pone.0227571.g004">Fig 4C</xref>) than BMSs.</p><fig id="pone.0227571.g003" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0227571.g003</object-id><label>Fig 3</label><caption><title>Subgroup analyses.</title><p>Subgroup analyses for patient characteristics are shown with HRs and 95% CIs for the primary composite outcome at the end of follow-up. ACEI, angiotensin converting enzyme inhibitor; ARB, angiotensin-II receptor blocker; BMS, bare-metal stent; DES, drug-eluting stent; CI, confidence interval; HR, hazard ratio; MCS, mechanical circulation support.</p></caption><graphic xlink:href="pone.0227571.g003"/></fig><fig id="pone.0227571.g004" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0227571.g004</object-id><label>Fig 4</label><caption><title>Cumulative event rate at 1-year follow-up using BMS, first- or second-generation DESs.</title><p>Cumulative event rate of revascularization (A), cardiovascular death (B) and primary composite outcome (C) associated with different stent types at 1-year follow-up. BMS, bare-metal stent; CV, cardiovascular; DES, drug-eluting stent.</p></caption><graphic xlink:href="pone.0227571.g004"/></fig></sec></sec><sec sec-type="conclusions" id="sec017"><title>Discussion</title><p>We found that among AF patients with a first AMI, the use of DESs, including both the first- and second- generation DESs, was associated with lower rates of cardiovascular death and primary composite outcome than BMSs within the first year and at the end of follow-up. While the greatest benefit from DES implantation was observed only within the first year of treatment, the outcomes were comparable upon prolonged follow-up. Regardless of the follow-up period, the cardiovascular benefits of DES were less apparent than BMS in patients with diabetes, CKD, or dialysis. Our study is the first to show an advantage in cardiovascular outcomes for DES compared to BMS in AF patients with first AMI requiring PCI.</p><p>In early trials of first-generation DES, the protocol-recommended DAPT duration was 3 to 6 months, but as a result of concerns about late thrombotic events, this was increased to 12 months in studies initiated after 2006 [<xref rid="pone.0227571.ref033" ref-type="bibr">33</xref>]. Coinciding with this shift, elderly patients or patients considered to be at high bleeding risk, high thrombotic risk, or low restenosis risk were largely excluded from the pivotal DES trials [<xref rid="pone.0227571.ref033" ref-type="bibr">33</xref>]. For the broad population, considering in-stent restenosis requiring revascularization, DESs are superior to BMSs within the first year of treatment [<xref rid="pone.0227571.ref034" ref-type="bibr">34</xref>]. Late in-stent restenosis occurs at approximately 1&#x02013;2% per year with all types of stents and is similar for first- and second-generation DESs and BMSs [<xref rid="pone.0227571.ref034" ref-type="bibr">34</xref>]. On the other hand, although the overall risk of stent thrombosis at up to 1 year is low and is comparable for both DESs and BMSs as long as patients are continued on DAPT for the recommended duration [<xref rid="pone.0227571.ref035" ref-type="bibr">35</xref>], late and very late stent thrombosis after first-generation DES implantation needs long-term DAPT [<xref rid="pone.0227571.ref036" ref-type="bibr">36</xref>]. However, the long-term cumulative rate of stent thrombosis in acute coronary syndrome patients does not differ between first generation DESs and BMSs (5.8% versus 4.3%, respectively) [<xref rid="pone.0227571.ref037" ref-type="bibr">37</xref>]. Collectively, the rates of the 2 major causes of stent failure, restenosis and thrombosis, appear to be comparable between DESs and BMSs beyond 1 year after treatment. The interplay between the improved thrombogenicity of DESs and the ability to reduce late loss&#x02013;related coronary events may be an explanation for these findings. Although BMSs are considered to minimize the duration of DAPT in post-stent AF patients to reduce the bleeding risk [<xref rid="pone.0227571.ref038" ref-type="bibr">38</xref>], the new-generation DESs are preferred over BMSs in such patients at low bleeding risk [<xref rid="pone.0227571.ref039" ref-type="bibr">39</xref>]. Furthermore, in post-PCI AF patients, a modified HAS-BLED score was unable to predict bleeding events [<xref rid="pone.0227571.ref040" ref-type="bibr">40</xref>]. Therefore, the choice between BMSs and DESs should not be based on the bleeding score. While our patients have a systematically mandated 1-year DAPT regimen, except in patients with high bleeding risk, the gastrointestinal and major bleeding rates were comparable between groups in our study. Altogether, these observations suggest that stent type is important in determining outcomes of AF patients with first AMI requiring PCI.</p><p>The use of DES in patients at high risk of bleeding or thrombosis has been recently studied. In ZEUS trial, among patients with uncertain ability to use DES with longer duration DAPT (median duration ~1 month) due to high bleeding, high thrombotic or low restenosis risk, second-generation zotarolimus-eluting stent was superior to BMS for clinical outcomes, including MI, stent thrombosis, and target lesion revascularization; bleeding risk was similar [<xref rid="pone.0227571.ref041" ref-type="bibr">41</xref>]. The LEADERS FREE trial showed that the composite primary safety end point of cardiac death, myocardial infarction, or stent thrombosis and the rate of the primary efficacy end point of clinically driven target-lesion revascularization.following biolimus A9 drug-coated stent implantation are lower than and superior to BMS in patients with high bleeding risk and who are able to take only 1 month of DAPT, while the latter strategy, driven by the need to minimize the risk of bleeding, is associated with a higher risk of restenosis and reintervention than that observed with the use of a DES [<xref rid="pone.0227571.ref042" ref-type="bibr">42</xref>]. Among elderly patients (age &#x02265;75 years) undergoing PCI with a shorter duration of DAPT, the SENIOR trial showed that the use of a bioabsorbable polymer-DES resulted in lower adverse clinical event rates, including the composite primary endpoint of all-cause mortality, myocardial infarction, stroke, or revascularization, at 1 year compared with BMS [<xref rid="pone.0227571.ref043" ref-type="bibr">43</xref>]. This benefit was driven predominantly due to a lower risk of repeat revascularization with DES [<xref rid="pone.0227571.ref043" ref-type="bibr">43</xref>]. Although PCI patients are typically managed with DAPT, antiplatelet therapy alone has been shown to be inadequate for stroke prevention in AF [<xref rid="pone.0227571.ref044" ref-type="bibr">44</xref>]. Hence, post-PCI AF patients are increasingly treated with DES and oral anticoagulants [<xref rid="pone.0227571.ref045" ref-type="bibr">45</xref>]. Altogether, these data provide further evidence that shorter durations of DAPT may be feasible with DES in select patient populations, especially where the temptation has been to use BMS to minimize DAPT duration. [<xref rid="pone.0227571.ref041" ref-type="bibr">41</xref>].</p><p>Our finding that 9.7% of AMI patients had a history of AF is similar to a previous study [<xref rid="pone.0227571.ref002" ref-type="bibr">2</xref>]. The risk of ischemic stroke is approximately 1% in post-PCI AF patients [<xref rid="pone.0227571.ref046" ref-type="bibr">46</xref>]. In our study, the risk was even higher at approximately 5% at 1 year and 8% at the end of follow-up in both groups, suggesting additive effects of the intracoronary and systemic prothrombotic environment accompanying AF and AMI. In post-stent AF patients, coadministration of DAPT and oral anticoagulants raises the concern about bleeding risk. Among post-PCI AF patients, triple therapy has been found to have no association with a reduction in death, ischemic stroke, target vessel revascularization, MI, or major bleeding events versus DAPT [<xref rid="pone.0227571.ref047" ref-type="bibr">47</xref>]. Additionally, in our study, the use of DESs compared with BMSs was associated with a reduction of death in AF patients with first AMI and received 1-year DAPT. Furthermore, while the rate of ischemic or hemorrhagic stroke, myocardial infarction, revascularization and gastrointestinal bleeding was comparable between groups, the use of DESs was associated with a reduced incidence of death, cardiovascular death and primary composite outcome. Taken together, these studies suggest that in AF patients with first AMI who received stents and 1-year DAPT, changes in the design of stent platform and other unmeasured factors may contribute to the clinical benefit of DESs over BMSs.</p><p>In subgroup analyses, the effect of DESs was similar to that of BMSs for primary composite outcome in our AF patients who had diabetes mellitus, CKD, or who were on dialysis. While the current opinion of the impact of diabetes mellitus on the outcome after PCI remains speculative, among ST-segment elevation MI patients undergoing primary PCI, DES implantation does mitigate the deleterious effect of diabetes on target vessel revascularization after BMS [<xref rid="pone.0227571.ref048" ref-type="bibr">48</xref>]. Few studies are available on the safety and efficacy of DES in CKD patients because these patients are systematically excluded from major interventional cardiology trials. Shenoy et al. demonstrated that selective use of DESs was safe and effective in patients with CKD in the long term, with lower risk of the composite of major adverse cardiovascular events, defined as death, MI or target vessel revascularization, and similar risk of MI compared with the use of BMSs [<xref rid="pone.0227571.ref049" ref-type="bibr">49</xref>]. The discordance between our findings and those of Shenoy et al. [<xref rid="pone.0227571.ref049" ref-type="bibr">49</xref>] are likely due to the patient differences in the clinical and angiographic characteristics and potentially dissimilar unmeasured confounders. On the other hand, the use of DESs compared to BMSs reduced the risk of all-cause mortality at 17 months in the study by Zhang et al. [<xref rid="pone.0227571.ref050" ref-type="bibr">50</xref>] and did not reduce mortality at 4 years in the study by Appleby et al [<xref rid="pone.0227571.ref051" ref-type="bibr">51</xref>]. However, they did not use any statistical designs (matching, covariate adjustment, or propensity-based adjustment) to adjust for differences between the DES and BMS patients. Of note, Appleby et al. found a significant survival benefit from DESs compared to BMSs in the first year after treatment (P = 0.002), with catch-up at 2 years (P = 0.057) [<xref rid="pone.0227571.ref051" ref-type="bibr">51</xref>].</p><p>Controversy remains regarding the efficacy of DES compared to BMS implantation in dialysis patients. While a study has demonstrated a reduced risk of recurrent MI, cardiovascular death, and all-cause mortality with the use of DESs compared with BMSs [<xref rid="pone.0227571.ref052" ref-type="bibr">52</xref>], none of the previous studies has focused on AF patients on dialysis with first AMI as the study population. Dialysis is reported to be an independent predictor of late catch-up phenomenon [<xref rid="pone.0227571.ref053" ref-type="bibr">53</xref>]. Whether the loss of DES treatment effects in AF patients with first AMI who had diabetes mellitus, CKD or dialysis is related to late catch-up phenomenon needs further studies.</p><p>Our study demonstrated a significantly lower cumulative incidence of cardiovascular death and primary composite outcome in the DES than BMS group within 1 year but a similar cumulative incidence from 1 year to end of the follow-up, which is similar to that of other studies [<xref rid="pone.0227571.ref054" ref-type="bibr">54</xref>]. Although late complications such as very late stent thrombosis and late catch-up phenomenon in patients after DES implantation have been previously reported [<xref rid="pone.0227571.ref053" ref-type="bibr">53</xref>], it is hard to define the exact rate of very late stent thrombosis because of the lack of data in the NHIRD. However, our results suggest a possible contribution of late catch-up phenomenon to cardiovascular death and primary composite outcome in AF patients with first AMI who received DES compared with those who received BMS. Further studies are warranted to elucidate this issue.</p><p>Our study has several limitations. First, our retrospective case-control study has a lower level of evidence than a prospective study. The common confounders of patient information, such as pre-infarction angina, family history of cardiovascular disease, smoking, body mass index, lipid profile, residual renal function, and dialyzer membrane type, were lacking in the NHIRD. Nonetheless, a wide range of variables associated with outcomes were included to match our 2 study groups. Second, although we analyzed repeat revascularizations, we could not determine the target vessel, target lesion revascularization, and different types of coronary revascularization. Third, the lack of clinical information in the claims database regarding stent thrombosis, angiographic characteristics, and lesion classification did not allow for a more detailed analysis. Finally, the available Taiwan NHIRD in our study included only inpatient claims data with no information of medications from the outpatient claims data and pharmacy claims data. Furthermore, although the DOAC has been covered by Taiwan&#x02019;s NHI system since 2012, our study period was from 1997 to 2011. Therefore, the use of oral anticoagulants was infrequent in our study. Nonetheless, the examination of large national databases is valuable, depending on an appropriate hypothesis, proper study design, and careful analysis of the results.</p><sec id="sec018"><title>Conclusions</title><p>Due to the complexity of treating AF patients who experience a first AMI requiring PCI, much effort should be made to come up with cost-effective treatment strategies. From the perspective of implanting a stent, the implantation of DESs compared with BMSs leads to a lower risk of primary composite outcome such as ischemic stroke, MI, revascularization, and death despite 1-year DAPT in both groups, suggesting differential prognostic impacts for DESs and BMSs. However, the effect is less apparent in patients with diabetes, CKD or on dialysis.</p></sec></sec><sec sec-type="supplementary-material" id="sec019"><title>Supporting information</title><supplementary-material content-type="local-data" id="pone.0227571.s001"><label>S1 Table</label><caption><title>ICD-9-CM code.</title><p>(DOC)</p></caption><media xlink:href="pone.0227571.s001.doc"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></sec></body><back><ack><p>We thank Alfred Hsing-Fen Lin and Zoe Ya-Jhu Syu for their assistance in statistical analysis.</p></ack><ref-list><title>References</title><ref id="pone.0227571.ref001"><label>1</label><mixed-citation publication-type="journal"><name><surname>Soliman</surname><given-names>EZ</given-names></name>, <name><surname>Safford</surname><given-names>MM</given-names></name>, <name><surname>Muntner</surname><given-names>P</given-names></name>, <name><surname>Khodneva</surname><given-names>Y</given-names></name>, <name><surname>Dawood</surname><given-names>FZ</given-names></name>, <name><surname>Zakai</surname><given-names>NA</given-names></name>, <etal>et al</etal>
<article-title>Atrial fibrillation and the risk of myocardial infarction</article-title>. <source>JAMA Intern Med</source>. <year>2014</year>; <volume>174</volume>:<fpage>107</fpage>&#x02013;<lpage>14</lpage>. <pub-id pub-id-type="doi">10.1001/jamainternmed.2013.11912</pub-id>
<pub-id pub-id-type="pmid">24190540</pub-id></mixed-citation></ref><ref id="pone.0227571.ref002"><label>2</label><mixed-citation publication-type="journal"><name><surname>Al Khdair</surname><given-names>D</given-names></name>, <name><surname>Alshengeiti</surname><given-names>L</given-names></name>, <name><surname>Elbarouni</surname><given-names>B</given-names></name>, <name><surname>Yan</surname><given-names>RT</given-names></name>, <name><surname>Grondin</surname><given-names>FR</given-names></name>, <name><surname>Spencer</surname><given-names>FA</given-names></name>, <etal>et al</etal>; <collab>Global Registry of Acute Coronary Events (GRACE/GRACE2) and the Canadian Registry of Coronary Events (CANRACE) Investigators</collab>. <article-title>Management and outcome of acute coronary syndrome patients in relation to prior history of atrial fibrillation</article-title>. <source>Can J Cardiol</source>. <year>2012</year>; <volume>28</volume>:<fpage>443</fpage>&#x02013;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1016/j.cjca.2011.12.011</pub-id>
<pub-id pub-id-type="pmid">22439969</pub-id></mixed-citation></ref><ref id="pone.0227571.ref003"><label>3</label><mixed-citation publication-type="journal"><name><surname>Violi</surname><given-names>F</given-names></name>, <name><surname>Soliman</surname><given-names>EZ</given-names></name>, <name><surname>Pignatelli</surname><given-names>P</given-names></name>, <name><surname>Pastori</surname><given-names>D</given-names></name>. <article-title>Atrial Fibrillation and Myocardial Infarction: A Systematic Review and Appraisal of Pathophysiologic Mechanisms</article-title>. <source>J Am Heart Assoc</source>. <year>2016</year>; <volume>5</volume>:<fpage>e003347</fpage>
<pub-id pub-id-type="doi">10.1161/jaha.116.003347</pub-id>
<pub-id pub-id-type="pmid">27208001</pub-id></mixed-citation></ref><ref id="pone.0227571.ref004"><label>4</label><mixed-citation publication-type="journal"><name><surname>Goto</surname><given-names>S</given-names></name>, <name><surname>Ikeda</surname><given-names>Y</given-names></name>, <name><surname>Shimada</surname><given-names>K</given-names></name>, <name><surname>Uchiyama</surname><given-names>S</given-names></name>, <name><surname>Origasa</surname><given-names>H</given-names></name>, <name><surname>Kobayashi</surname><given-names>H</given-names></name>; <collab>J-TRACE Investigators</collab>. <article-title>One-year cardiovascular event rates in Japanese outpatients with myocardial infarction, stroke, and atrial fibrillation. -Results From the Japan Thrombosis Registry for Atrial Fibrillation, Coronary, or Cerebrovascular Events (J-TRACE)</article-title>. <source>Circ J</source>. <year>2011</year>; <volume>75</volume>:<fpage>2598</fpage>&#x02013;<lpage>604</lpage>. <pub-id pub-id-type="doi">10.1253/circj.cj-11-0378</pub-id>
<pub-id pub-id-type="pmid">21857143</pub-id></mixed-citation></ref><ref id="pone.0227571.ref005"><label>5</label><mixed-citation publication-type="journal"><name><surname>Aoki</surname><given-names>J</given-names></name>, <name><surname>Lansky</surname><given-names>AJ</given-names></name>, <name><surname>Mehran</surname><given-names>R</given-names></name>, <name><surname>Moses</surname><given-names>J</given-names></name>, <name><surname>Bertrand</surname><given-names>ME</given-names></name>, <name><surname>McLaurin</surname><given-names>BT</given-names></name>, <etal>et al</etal>
<article-title>Early stent thrombosis in patients with acute coronary syndromes treated with drug-eluting and bare metal stents: the Acute Catheterization and Urgent Intervention Triage Strategy trial</article-title>. <source>Circulation</source>. <year>2009</year>; <volume>119</volume>:<fpage>687</fpage>&#x02013;<lpage>98</lpage>. <pub-id pub-id-type="doi">10.1161/circulationaha.108.804203</pub-id>
<pub-id pub-id-type="pmid">19171852</pub-id></mixed-citation></ref><ref id="pone.0227571.ref006"><label>6</label><mixed-citation publication-type="journal"><name><surname>Mao</surname><given-names>CT</given-names></name>, <name><surname>Chen</surname><given-names>TH</given-names></name>, <name><surname>Tseng</surname><given-names>CN</given-names></name>, <name><surname>Chen</surname><given-names>SW</given-names></name>, <name><surname>Hsieh</surname><given-names>IC</given-names></name>, <name><surname>Hung</surname><given-names>MJ</given-names></name>, <etal>et al</etal>
<article-title>Clinical outcomes of second-generation limus-eluting stents compared to paclitaxel-eluting stents for acute myocardial infarction with cardiogenic shock</article-title>. <source>PLoS One</source>. <year>2019</year>; <volume>14</volume>:<fpage>e0214417</fpage>
<pub-id pub-id-type="doi">10.1371/journal.pone.0214417</pub-id>
<pub-id pub-id-type="pmid">30943217</pub-id></mixed-citation></ref><ref id="pone.0227571.ref007"><label>7</label><mixed-citation publication-type="journal"><name><surname>Sambola</surname><given-names>A</given-names></name>, <name><surname>Mutuberr&#x000ed;a</surname><given-names>M</given-names></name>, <name><surname>Garc&#x000ed;a Del Blanco</surname><given-names>B</given-names></name>, <name><surname>Alonso</surname><given-names>A</given-names></name>, <name><surname>Barrab&#x000e9;s</surname><given-names>JA</given-names></name>, <name><surname>Bueno</surname><given-names>H</given-names></name>, <etal>et al</etal>
<article-title>Impact of Triple Therapy in Elderly Patients with Atrial Fibrillation Undergoing Percutaneous Coronary Intervention</article-title>. <source>PLoS One</source>. <year>2016</year>; <volume>11</volume>:<fpage>e0147245</fpage>
<pub-id pub-id-type="doi">10.1371/journal.pone.0147245</pub-id>
<pub-id pub-id-type="pmid">26808678</pub-id></mixed-citation></ref><ref id="pone.0227571.ref008"><label>8</label><mixed-citation publication-type="journal"><collab>European Heart Rhythm Association</collab>; <collab>Heart Rhythm Society</collab>, <name><surname>Fuster</surname><given-names>V</given-names></name>, <name><surname>Ryd&#x000e9;n</surname><given-names>LE</given-names></name>, <name><surname>Cannom</surname><given-names>DS</given-names></name>, <name><surname>Crijns</surname><given-names>HJ</given-names></name>, <name><surname>Curtis</surname><given-names>AB</given-names></name>, <name><surname>Ellenbogen</surname><given-names>KA</given-names></name>, <etal>et al</etal>; <collab>American College of Cardiology</collab>; <collab>American Heart Association Task Force on Practice Guidelines</collab>; <collab>European Society of Cardiology Committee for Practice Guidelines</collab>; <collab>Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation</collab>. <article-title>ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation&#x02014;executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation)</article-title>. <source>J Am Coll Cardiol</source>. <year>2006</year>; <volume>48</volume>:<fpage>854</fpage>&#x02013;<lpage>906</lpage>. <pub-id pub-id-type="doi">10.1016/j.jacc.2006.07.009</pub-id>
<pub-id pub-id-type="pmid">16904574</pub-id></mixed-citation></ref><ref id="pone.0227571.ref009"><label>9</label><mixed-citation publication-type="journal"><name><surname>January</surname><given-names>CT</given-names></name>, <name><surname>Wann</surname><given-names>LS</given-names></name>, <name><surname>Alpert</surname><given-names>JS</given-names></name>, <name><surname>Calkins</surname><given-names>H</given-names></name>, <name><surname>Cigarroa</surname><given-names>JE</given-names></name>, <name><surname>Cleveland</surname><given-names>JC</given-names><suffix>Jr</suffix></name>, <etal>et al</etal>; <collab>American College of Cardiology/American Heart Association Task Force on Practice Guidelines</collab>. <article-title>2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society</article-title>. <source>J Am Coll Cardiol</source>. <year>2014</year>; <volume>64</volume>:<fpage>e1</fpage>&#x02013;<lpage>e76</lpage>. <pub-id pub-id-type="doi">10.1016/j.jacc.2014.03.022</pub-id>
<pub-id pub-id-type="pmid">24685669</pub-id></mixed-citation></ref><ref id="pone.0227571.ref010"><label>10</label><mixed-citation publication-type="journal"><name><surname>Kirchhof</surname><given-names>P</given-names></name>, <name><surname>Benussi</surname><given-names>S</given-names></name>, <name><surname>Kotecha</surname><given-names>D</given-names></name>, <name><surname>Ahlsson</surname><given-names>A</given-names></name>, <name><surname>Atar</surname><given-names>D</given-names></name>, <name><surname>Casadei</surname><given-names>B</given-names></name>, <etal>et al</etal>
<article-title>2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS</article-title>. <source>Eur Heart J</source>. <year>2016</year>; <volume>37</volume>:<fpage>2893</fpage>&#x02013;<lpage>962</lpage>. <pub-id pub-id-type="doi">10.1093/eurheartj/ehw210</pub-id>
<pub-id pub-id-type="pmid">27567408</pub-id></mixed-citation></ref><ref id="pone.0227571.ref011"><label>11</label><mixed-citation publication-type="journal"><name><surname>Dewilde</surname><given-names>WJ</given-names></name>, <name><surname>Oirbans</surname><given-names>T</given-names></name>, <name><surname>Verheugt</surname><given-names>FW</given-names></name>, <name><surname>Kelder</surname><given-names>JC</given-names></name>, <name><surname>De Smet</surname><given-names>BJ</given-names></name>, <name><surname>Herrman</surname><given-names>JP</given-names></name>, <etal>et al</etal>; <collab>WOEST study investigators</collab>. <article-title>Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial</article-title>. <source>Lancet</source>. <year>2013</year>; <volume>381</volume>:<fpage>1107</fpage>&#x02013;<lpage>15</lpage>. <pub-id pub-id-type="doi">10.1016/S0140-6736(12)62177-1</pub-id>
<pub-id pub-id-type="pmid">23415013</pub-id></mixed-citation></ref><ref id="pone.0227571.ref012"><label>12</label><mixed-citation publication-type="journal"><name><surname>Braun</surname><given-names>O&#x000d6;</given-names></name>, <name><surname>Bico</surname><given-names>B</given-names></name>, <name><surname>Chaudhry</surname><given-names>U</given-names></name>, <name><surname>Wagner</surname><given-names>H</given-names></name>, <name><surname>Koul</surname><given-names>S</given-names></name>, <name><surname>Tyd&#x000e9;n</surname><given-names>P</given-names></name>, <etal>et al</etal>
<article-title>Concomitant use of warfarin and ticagrelor as an alternative to triple antithrombotic therapy after an acute coronary syndrome</article-title>. <source>Thromb Res</source>. <year>2015</year>; <volume>135</volume>:<fpage>26</fpage>&#x02013;<lpage>30</lpage>. <pub-id pub-id-type="doi">10.1016/j.thromres.2014.10.016</pub-id>
<pub-id pub-id-type="pmid">25467434</pub-id></mixed-citation></ref><ref id="pone.0227571.ref013"><label>13</label><mixed-citation publication-type="journal"><name><surname>January</surname><given-names>CT</given-names></name>, <name><surname>Wann</surname><given-names>LS</given-names></name>, <name><surname>Calkins</surname><given-names>H</given-names></name>, <name><surname>Chen</surname><given-names>LY</given-names></name>, <name><surname>Cigarroa</surname><given-names>JE</given-names></name>, <name><surname>Cleveland</surname><given-names>JC</given-names><suffix>Jr</suffix></name>, <etal>et al</etal>
<article-title>2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society in Collaboration With the Society of Thoracic Surgeons</article-title>. <source>Circulation</source>. <year>2019</year>; <volume>140</volume>:<fpage>e125</fpage>&#x02013;<lpage>e151</lpage>. <pub-id pub-id-type="doi">10.1161/CIR.0000000000000665</pub-id>
<pub-id pub-id-type="pmid">30686041</pub-id></mixed-citation></ref><ref id="pone.0227571.ref014"><label>14</label><mixed-citation publication-type="journal"><name><surname>Gibson</surname><given-names>CM</given-names></name>, <name><surname>Mehran</surname><given-names>R</given-names></name>, <name><surname>Bode</surname><given-names>C</given-names></name>, <name><surname>Halperin</surname><given-names>J</given-names></name>, <name><surname>Verheugt</surname><given-names>FW</given-names></name>, <name><surname>Wildgoose</surname><given-names>P</given-names></name>, <etal>et al</etal>
<article-title>Prevention of Bleeding in Patients with Atrial Fibrillation Undergoing PCI</article-title>. <source>N Engl J Med</source>. <year>2016</year>; <volume>375</volume>:<fpage>2423</fpage>&#x02013;<lpage>34</lpage>. <pub-id pub-id-type="doi">10.1056/NEJMoa1611594</pub-id>
<pub-id pub-id-type="pmid">27959713</pub-id></mixed-citation></ref><ref id="pone.0227571.ref015"><label>15</label><mixed-citation publication-type="journal"><name><surname>Cannon</surname><given-names>CP</given-names></name>, <name><surname>Bhatt</surname><given-names>DL</given-names></name>, <name><surname>Oldgren</surname><given-names>J</given-names></name>, <name><surname>Lip</surname><given-names>GYH</given-names></name>, <name><surname>Ellis</surname><given-names>SG</given-names></name>, <name><surname>Kimura</surname><given-names>T</given-names></name>, <etal>et al</etal>; <collab>RE-DUAL PCI Steering Committee and Investigators</collab>. <article-title>Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial Fibrillation</article-title>. <source>N Engl J Med</source>. <year>2017</year>; <volume>377</volume>:<fpage>1513</fpage>&#x02013;<lpage>24</lpage>. <pub-id pub-id-type="doi">10.1056/NEJMoa1708454</pub-id>
<pub-id pub-id-type="pmid">28844193</pub-id></mixed-citation></ref><ref id="pone.0227571.ref016"><label>16</label><mixed-citation publication-type="journal"><name><surname>Angiolillo</surname><given-names>DJ</given-names></name>, <name><surname>Goodman</surname><given-names>SG</given-names></name>, <name><surname>Bhatt</surname><given-names>DL</given-names></name>, <name><surname>Eikelboom</surname><given-names>JW</given-names></name>, <name><surname>Price</surname><given-names>MJ</given-names></name>, <name><surname>Moliterno</surname><given-names>DJ</given-names></name>, <etal>et al</etal>
<article-title>Antithrombotic Therapy in Patients With Atrial Fibrillation Treated With Oral Anticoagulation Undergoing Percutaneous Coronary Intervention</article-title>. <source>Circulation</source>. <year>2018</year>; <volume>138</volume>:<fpage>527</fpage>&#x02013;<lpage>36</lpage>. <pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.118.034722</pub-id>
<pub-id pub-id-type="pmid">30571525</pub-id></mixed-citation></ref><ref id="pone.0227571.ref017"><label>17</label><mixed-citation publication-type="journal"><name><surname>O&#x02019;Gara</surname><given-names>PT</given-names></name>, <name><surname>Kushner</surname><given-names>FG</given-names></name>, <name><surname>Ascheim</surname><given-names>DD</given-names></name>, <name><surname>Casey</surname><given-names>DE</given-names><suffix>Jr</suffix></name>, <name><surname>Chung</surname><given-names>MK</given-names></name>, <name><surname>de Lemos</surname><given-names>JA</given-names></name>, <etal>et al</etal>
<article-title>2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines</article-title>. <source>J Am Coll Cardiol</source>. <year>2013</year>; <volume>61</volume>:<fpage>e78</fpage>&#x02013;<lpage>e140</lpage>. <pub-id pub-id-type="doi">10.1016/j.jacc.2012.11.019</pub-id>
<pub-id pub-id-type="pmid">23256914</pub-id></mixed-citation></ref><ref id="pone.0227571.ref018"><label>18</label><mixed-citation publication-type="journal"><name><surname>Faxon</surname><given-names>DP</given-names></name>, <name><surname>Eikelboom</surname><given-names>JW</given-names></name>, <name><surname>Berger</surname><given-names>PB</given-names></name>, <name><surname>Holmes</surname><given-names>DR</given-names><suffix>Jr</suffix></name>, <name><surname>Bhatt</surname><given-names>DL</given-names></name>, <name><surname>Moliterno</surname><given-names>DJ</given-names></name>, <etal>et al</etal>
<article-title>Antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting: a North American perspective: executive summary</article-title>. <source>Circ Cardiovasc Interv</source>. <year>2011</year>; <volume>4</volume>:<fpage>522</fpage>&#x02013;<lpage>34</lpage>. <pub-id pub-id-type="doi">10.1161/CIRCINTERVENTIONS.111.965186</pub-id>
<pub-id pub-id-type="pmid">22010191</pub-id></mixed-citation></ref><ref id="pone.0227571.ref019"><label>19</label><mixed-citation publication-type="journal"><name><surname>Levine</surname><given-names>GN</given-names></name>, <name><surname>Bates</surname><given-names>ER</given-names></name>, <name><surname>Blankenship</surname><given-names>JC</given-names></name>, <name><surname>Bailey</surname><given-names>SR</given-names></name>, <name><surname>Bittl</surname><given-names>JA</given-names></name>, <name><surname>Cercek</surname><given-names>B</given-names></name>, <etal>et al</etal>; <collab>American College of Cardiology Foundation</collab>; <collab>American Heart Association Task Force on Practice Guidelines</collab>; <collab>Society for Cardiovascular Angiography and Interventions</collab>. <article-title>2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions</article-title>. <source>J Am Coll Cardiol</source>. <year>2011</year>; <volume>58</volume>:<fpage>e44</fpage>&#x02013;<lpage>122</lpage>. <pub-id pub-id-type="doi">10.1016/j.jacc.2011.08.007</pub-id>
<pub-id pub-id-type="pmid">22070834</pub-id></mixed-citation></ref><ref id="pone.0227571.ref020"><label>20</label><mixed-citation publication-type="journal"><name><surname>Angiolillo</surname><given-names>DJ</given-names></name>, <name><surname>Goodman</surname><given-names>SG</given-names></name>, <name><surname>Bhatt</surname><given-names>DL</given-names></name>, <name><surname>Eikelboom</surname><given-names>JW</given-names></name>, <name><surname>Price</surname><given-names>MJ</given-names></name>, <name><surname>Moliterno</surname><given-names>DJ</given-names></name>, <etal>et al</etal>
<article-title>Antithrombotic Therapy in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention: A North American Perspective-2016 Update</article-title>. <source>Circ Cardiovasc Interv</source>. <year>2016</year>; <volume>9</volume> e004395. <pub-id pub-id-type="doi">10.1161/CIRCINTERVENTIONS.116.004395</pub-id>
<pub-id pub-id-type="pmid">27803042</pub-id></mixed-citation></ref><ref id="pone.0227571.ref021"><label>21</label><mixed-citation publication-type="journal"><name><surname>Lip</surname><given-names>GY</given-names></name>, <name><surname>Windecker</surname><given-names>S</given-names></name>, <name><surname>Huber</surname><given-names>K</given-names></name>, <name><surname>Kirchhof</surname><given-names>P</given-names></name>, <name><surname>Marin</surname><given-names>F</given-names></name>, <name><surname>Ten Berg</surname><given-names>JM</given-names></name>, <etal>et al</etal>
<article-title>Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary or valve interventions: a joint consensus document of the European Society of Cardiology Working Group on Thrombosis, European Heart Rhythm Association (EHRA), European Association of Percutaneous Cardiovascular Interventions (EAPCI) and European Association of Acute Cardiac Care (ACCA) endorsed by the Heart Rhythm Society (HRS) and Asia-Pacific Heart Rhythm Society (APHRS)</article-title>. <source>Eur Heart J</source>. <year>2014</year>; <volume>35</volume>:<fpage>3155</fpage>&#x02013;<lpage>79</lpage>. <pub-id pub-id-type="doi">10.1093/eurheartj/ehu298</pub-id>
<pub-id pub-id-type="pmid">25154388</pub-id></mixed-citation></ref><ref id="pone.0227571.ref022"><label>22</label><mixed-citation publication-type="journal"><name><surname>Russ</surname><given-names>MA</given-names></name>, <name><surname>Wackerl</surname><given-names>C</given-names></name>, <name><surname>Zeymer</surname><given-names>U</given-names></name>, <name><surname>Hochadel</surname><given-names>M</given-names></name>, <name><surname>Kerber</surname><given-names>S</given-names></name>, <name><surname>Zahn</surname><given-names>R</given-names></name>, <etal>et al</etal>; <collab>ALKK-Study Group</collab>. <article-title>Gender based differences in drug eluting stent implantation&#x02014;data from the German ALKK registry suggest underuse of DES in elderly women</article-title>. <source>BMC Cardiovasc Disord</source>. <year>2017</year>; <volume>17</volume>:<fpage>68</fpage>
<pub-id pub-id-type="doi">10.1186/s12872-017-0500-y</pub-id>
<pub-id pub-id-type="pmid">28241861</pub-id></mixed-citation></ref><ref id="pone.0227571.ref023"><label>23</label><mixed-citation publication-type="journal"><name><surname>Kim</surname><given-names>C</given-names></name>, <name><surname>Redberg</surname><given-names>RF</given-names></name>, <name><surname>Pavlic</surname><given-names>T</given-names></name>, <name><surname>Eagle</surname><given-names>KA</given-names></name>. <article-title>A systematic review of gender differences in mortality after coronary artery bypass graft surgery and percutaneous coronary interventions</article-title>. <source>Clin Cardiol</source>. <year>2007</year>; <volume>30</volume>:<fpage>491</fpage>&#x02013;<lpage>5</lpage>. <pub-id pub-id-type="doi">10.1002/clc.20000</pub-id>
<pub-id pub-id-type="pmid">17880013</pub-id></mixed-citation></ref><ref id="pone.0227571.ref024"><label>24</label><mixed-citation publication-type="journal"><name><surname>Hsing</surname><given-names>AW</given-names></name>, <name><surname>Ioannidis</surname><given-names>JP</given-names></name>. <article-title>Nationwide Population Science: Lessons From the Taiwan National Health Insurance Research Database</article-title>. <source>JAMA Intern Med</source>. <year>2015</year>; <volume>175</volume>:<fpage>1527</fpage>&#x02013;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1001/jamainternmed.2015.3540</pub-id>
<pub-id pub-id-type="pmid">26192815</pub-id></mixed-citation></ref><ref id="pone.0227571.ref025"><label>25</label><mixed-citation publication-type="journal"><name><surname>Lin</surname><given-names>LY</given-names></name>, <name><surname>Warren-Gash</surname><given-names>C</given-names></name>, <name><surname>Smeeth</surname><given-names>L</given-names></name>, <name><surname>Chen</surname><given-names>PC</given-names></name>. <article-title>Data resource profile: the National Health Insurance Research Database (NHIRD)</article-title>. <source>Epidemiol Health</source>. <year>2018</year>;<volume>40</volume>:<fpage>e2018062</fpage>
<pub-id pub-id-type="doi">10.4178/epih.e2018062</pub-id>
<pub-id pub-id-type="pmid">30727703</pub-id></mixed-citation></ref><ref id="pone.0227571.ref026"><label>26</label><mixed-citation publication-type="journal"><name><surname>Hsieh</surname><given-names>CY</given-names></name>, <name><surname>Su</surname><given-names>CC</given-names></name>, <name><surname>Shao</surname><given-names>SC</given-names></name>, <name><surname>Sung</surname><given-names>SF</given-names></name>, <name><surname>Lin</surname><given-names>SJ</given-names></name>, <name><surname>Kao Yang</surname><given-names>YH</given-names></name>, <etal>et al</etal>
<article-title>Taiwan&#x02019;s National Health Insurance Research Database: past and future</article-title>. <source>Clin Epidemiol</source>. <year>2019</year>
<month>5</month>
<day>3</day>;<volume>11</volume>:<fpage>349</fpage>&#x02013;<lpage>58</lpage>. <pub-id pub-id-type="doi">10.2147/CLEP.S196293</pub-id>
<pub-id pub-id-type="pmid">31118821</pub-id></mixed-citation></ref><ref id="pone.0227571.ref027"><label>27</label><mixed-citation publication-type="journal"><name><surname>Cheng</surname><given-names>CL</given-names></name>, <name><surname>Lee</surname><given-names>CH</given-names></name>, <name><surname>Chen</surname><given-names>PS</given-names></name>, <name><surname>Li</surname><given-names>YH</given-names></name>, <name><surname>Lin</surname><given-names>SJ</given-names></name>, <name><surname>Yang</surname><given-names>YH</given-names></name>. <article-title>Validation of acute myocardial infarction cases in the national health insurance research database in taiwan</article-title>. <source>J Epidemiol</source>. <year>2014</year>; <volume>24</volume>:<fpage>500</fpage>&#x02013;<lpage>7</lpage>. <pub-id pub-id-type="doi">10.2188/jea.je20140076</pub-id>
<pub-id pub-id-type="pmid">25174915</pub-id></mixed-citation></ref><ref id="pone.0227571.ref028"><label>28</label><mixed-citation publication-type="journal"><name><surname>Chen</surname><given-names>DY</given-names></name>, <name><surname>Mao</surname><given-names>CT</given-names></name>, <name><surname>Tsai</surname><given-names>ML</given-names></name>, <name><surname>Chen</surname><given-names>SW</given-names></name>, <name><surname>Lin</surname><given-names>YS</given-names></name>, <name><surname>Hsieh</surname><given-names>IC</given-names></name>, <etal>et al</etal>
<article-title>Clinical outcomes of drug-eluting stents versus bare-metal stents in patients with cardiogenic shock complicating acute myocardial infarction</article-title>. <source>Int J Cardiol</source>. <year>2016</year>; <volume>215</volume>:<fpage>98</fpage>&#x02013;<lpage>104</lpage>. <pub-id pub-id-type="doi">10.1016/j.ijcard.2016.04.014</pub-id>
<pub-id pub-id-type="pmid">27111168</pub-id></mixed-citation></ref><ref id="pone.0227571.ref029"><label>29</label><mixed-citation publication-type="journal"><name><surname>Hsieh</surname><given-names>CY</given-names></name>, <name><surname>Chen</surname><given-names>CH</given-names></name>, <name><surname>Li</surname><given-names>CY</given-names></name>, <name><surname>Lai</surname><given-names>ML</given-names></name>. <article-title>Validating the diagnosis of acute ischemic stroke in a National Health Insurance claims database</article-title>. <source>J Formos Med Assoc</source>. <year>2015</year>; <volume>114</volume>:<fpage>254</fpage>&#x02013;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1016/j.jfma.2013.09.009</pub-id>
<pub-id pub-id-type="pmid">24140108</pub-id></mixed-citation></ref><ref id="pone.0227571.ref030"><label>30</label><mixed-citation publication-type="journal"><name><surname>Wu</surname><given-names>CY</given-names></name>, <name><surname>Chen</surname><given-names>YJ</given-names></name>, <name><surname>Ho</surname><given-names>HJ</given-names></name>, <name><surname>Hsu</surname><given-names>YC</given-names></name>, <name><surname>Kuo</surname><given-names>KN</given-names></name>, <name><surname>Wu</surname><given-names>MS</given-names></name>, <etal>et al</etal>
<article-title>Association between nucleoside analogues and risk of hepatitis B virus-related hepatocellular carcinoma recurrence following liver resection</article-title>. <source>JAMA</source>. <year>2012</year>; <volume>308</volume>:<fpage>1906</fpage>&#x02013;<lpage>14</lpage>. <pub-id pub-id-type="doi">10.1001/2012.jama.11975</pub-id>
<pub-id pub-id-type="pmid">23162861</pub-id></mixed-citation></ref><ref id="pone.0227571.ref031"><label>31</label><mixed-citation publication-type="other">Hicks KA, Hung HMJ, Mahaffey KW, Mehran R, Nissen SE, Stockbridge NL, et al; for Standardized Data Collection for Cardiovascular Trials Initiative. Standardized Definitions for End Point Events in Cardiovascular Trials. US Food &#x00026; Drug Administration. 2010.</mixed-citation></ref><ref id="pone.0227571.ref032"><label>32</label><mixed-citation publication-type="journal"><name><surname>Chen</surname><given-names>DY</given-names></name>, <name><surname>Mao</surname><given-names>CT</given-names></name>, <name><surname>Tsai</surname><given-names>ML</given-names></name>, <name><surname>Hsieh</surname><given-names>MJ</given-names></name>, <name><surname>Lin</surname><given-names>YS</given-names></name>, <name><surname>Cherng</surname><given-names>WJ</given-names></name>, <etal>et al</etal>
<article-title>Clinical Outcomes of Drug-Eluting Stents vs. Bare-Metal Stents in Acute Myocardial Infarction Patients Under Dialysis&#x02014;A Nationwide Cohort Study</article-title>. <source>Circ J</source>. <year>2016</year>; <volume>80</volume>:<fpage>363</fpage>&#x02013;<lpage>70</lpage>. <pub-id pub-id-type="doi">10.1253/circj.CJ-15-0778</pub-id>
<pub-id pub-id-type="pmid">26581755</pub-id></mixed-citation></ref><ref id="pone.0227571.ref033"><label>33</label><mixed-citation publication-type="journal"><name><surname>King</surname><given-names>SB</given-names><suffix>3rd</suffix></name>, <name><surname>Smith</surname><given-names>SC</given-names><suffix>Jr</suffix></name>, <name><surname>Hirshfeld</surname><given-names>JW</given-names><suffix>Jr</suffix></name>, <name><surname>Jacobs</surname><given-names>AK</given-names></name>, <name><surname>Morrison</surname><given-names>DA</given-names></name>, <name><surname>Williams</surname><given-names>DO</given-names></name>; <collab>2005 WRITING COMMITTEE MEMBERS</collab>, <name><surname>Feldman</surname><given-names>TE</given-names></name>, <name><surname>Kern</surname><given-names>MJ</given-names></name>, <name><surname>O&#x02019;Neill</surname><given-names>WW</given-names></name>, <name><surname>Schaff</surname><given-names>HV</given-names></name>, <name><surname>Whitlow</surname><given-names>PL</given-names></name>, <name><surname>Adams</surname><given-names>CD</given-names></name>, <name><surname>Anderson</surname><given-names>JL</given-names></name>, <name><surname>Buller</surname><given-names>CE</given-names></name>, <name><surname>Creager</surname><given-names>MA</given-names></name>, <name><surname>Ettinger</surname><given-names>SM</given-names></name>, <name><surname>Halperin</surname><given-names>JL</given-names></name>, <name><surname>Hunt</surname><given-names>SA</given-names></name>, <name><surname>Krumholz</surname><given-names>HM</given-names></name>, <name><surname>Kushner</surname><given-names>FG</given-names></name>, <name><surname>Lytle</surname><given-names>BW</given-names></name>, <name><surname>Nishimura</surname><given-names>R</given-names></name>, <name><surname>Page</surname><given-names>RL</given-names></name>, <name><surname>Riegel</surname><given-names>B</given-names></name>, <name><surname>Tarkington</surname><given-names>LG</given-names></name>, <name><surname>Yancy</surname><given-names>CW</given-names></name>. <article-title>2007 Focused Update of the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines: 2007 Writing Group to Review New Evidence and Update the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention, Writing on Behalf of the 2005 Writing Committee</article-title>. <source>Circulation</source>. <year>2008</year>; <volume>117</volume>:<fpage>261</fpage>&#x02013;<lpage>95</lpage>. <pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.107.188208</pub-id>
<pub-id pub-id-type="pmid">18079354</pub-id></mixed-citation></ref><ref id="pone.0227571.ref034"><label>34</label><mixed-citation publication-type="journal"><name><surname>Ellis</surname><given-names>SG</given-names></name>, <name><surname>Stone</surname><given-names>GW</given-names></name>, <name><surname>Cox</surname><given-names>DA</given-names></name>, <name><surname>Hermiller</surname><given-names>J</given-names></name>, <name><surname>O&#x02019;Shaughnessy</surname><given-names>C</given-names></name>, <name><surname>Mann</surname><given-names>T</given-names></name>, <etal>et al</etal>, <collab>TAXUS IV Investigators</collab>. <article-title>Long-term safety and efficacy with paclitaxel-eluting stents: 5-year final results of the TAXUS IV clinical trial (TAXUS IV-SR: Treatment of De Novo Coronary Disease Using a Single Paclitaxel-Eluting Stent)</article-title>. <source>JACC Cardiovasc Interv</source>. <year>2009</year>; <volume>2</volume>:<fpage>1248</fpage>&#x02013;<lpage>59</lpage>. <pub-id pub-id-type="doi">10.1016/j.jcin.2009.10.003</pub-id>
<pub-id pub-id-type="pmid">20129552</pub-id></mixed-citation></ref><ref id="pone.0227571.ref035"><label>35</label><mixed-citation publication-type="journal"><name><surname>Lagerqvist</surname><given-names>B</given-names></name>, <name><surname>James</surname><given-names>SK</given-names></name>, <name><surname>Stenestrand</surname><given-names>U</given-names></name>, <name><surname>Lindb&#x000e4;ck</surname><given-names>J</given-names></name>, <name><surname>Nilsson</surname><given-names>T</given-names></name>, <name><surname>Wallentin</surname><given-names>L</given-names></name>; <collab>SCAAR Study Group</collab>. <article-title>Long-term outcomes with drug-eluting stents versus bare-metal stents in Sweden</article-title>. <source>N Engl J Med</source>. <year>2007</year>; <volume>356</volume>:<fpage>1009</fpage>&#x02013;<lpage>19</lpage>. <pub-id pub-id-type="doi">10.1056/nejmoa067722</pub-id>
<pub-id pub-id-type="pmid">17296822</pub-id></mixed-citation></ref><ref id="pone.0227571.ref036"><label>36</label><mixed-citation publication-type="journal"><name><surname>McFadden</surname><given-names>EP</given-names></name>, <name><surname>Stabile</surname><given-names>E</given-names></name>, <name><surname>Regar</surname><given-names>E</given-names></name>, <name><surname>Cheneau</surname><given-names>E</given-names></name>, <name><surname>Ong</surname><given-names>AT</given-names></name>, <name><surname>Kinnaird</surname><given-names>T</given-names></name>, <etal>et al</etal>
<article-title>Late thrombosis in drug-eluting coronary stents after discontinuation of antiplatelet therapy</article-title>. <source>Lancet</source>. <year>2004</year>; <volume>364</volume>:<fpage>1519</fpage>&#x02013;<lpage>21</lpage>. <pub-id pub-id-type="doi">10.1016/s0140-6736(04)17275-9</pub-id>
<pub-id pub-id-type="pmid">15500897</pub-id></mixed-citation></ref><ref id="pone.0227571.ref037"><label>37</label><mixed-citation publication-type="journal"><name><surname>De Luca</surname><given-names>G</given-names></name>, <name><surname>Dirksen</surname><given-names>MT</given-names></name>, <name><surname>Spaulding</surname><given-names>C</given-names></name>, <name><surname>Kelbaek</surname><given-names>H</given-names></name>, <name><surname>Schalij</surname><given-names>M</given-names></name>, <name><surname>Thuesen</surname><given-names>L</given-names></name>, <etal>et al</etal>; <collab>Drug-Eluting Stent in Primary Angioplasty (DESERT) Cooperation</collab>. <article-title>Drug-eluting vs bare-metal stents in primary angioplasty: a pooled patient-level meta-analysis of randomized trials</article-title>. <source>Arch Intern Med</source>. <year>2012</year>; <volume>172</volume>:<fpage>611</fpage>&#x02013;<lpage>21</lpage>. <pub-id pub-id-type="doi">10.1001/archinternmed.2012.758</pub-id>
<pub-id pub-id-type="pmid">22529227</pub-id></mixed-citation></ref><ref id="pone.0227571.ref038"><label>38</label><mixed-citation publication-type="journal"><name><surname>January</surname><given-names>CT</given-names></name>, <name><surname>Wann</surname><given-names>LS</given-names></name>, <name><surname>Alpert</surname><given-names>JS</given-names></name>, <name><surname>Calkins</surname><given-names>H</given-names></name>, <name><surname>Cigarroa</surname><given-names>JE</given-names></name>, <name><surname>Cleveland</surname><given-names>JC</given-names><suffix>Jr</suffix></name>, <etal>et al</etal>; <collab>ACC/AHA Task Force Members</collab>. <article-title>2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society</article-title>. <source>Circulation</source>. <year>2014</year>; <volume>130</volume>:<fpage>e199</fpage>&#x02013;<lpage>267</lpage>. <pub-id pub-id-type="doi">10.1161/cir.0000000000000041</pub-id>
<pub-id pub-id-type="pmid">24682347</pub-id></mixed-citation></ref><ref id="pone.0227571.ref039"><label>39</label><mixed-citation publication-type="journal"><collab>Authors/Task Force members</collab>, <name><surname>Windecker</surname><given-names>S</given-names></name>, <name><surname>Kolh</surname><given-names>P</given-names></name>, <name><surname>Alfonso</surname><given-names>F</given-names></name>, <name><surname>Collet</surname><given-names>JP</given-names></name>, <name><surname>Cremer</surname><given-names>J</given-names></name>, <name><surname>Falk</surname><given-names>V</given-names></name>, <etal>et al</etal>
<article-title>2014 ESC/EACTS Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS) Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI)</article-title>. <source>Eur Heart J</source>. <year>2014</year>; <volume>35</volume>:<fpage>2541</fpage>&#x02013;<lpage>619</lpage>. <pub-id pub-id-type="doi">10.1093/eurheartj/ehu278</pub-id>
<pub-id pub-id-type="pmid">25173339</pub-id></mixed-citation></ref><ref id="pone.0227571.ref040"><label>40</label><mixed-citation publication-type="journal"><name><surname>Puurunen</surname><given-names>MK</given-names></name>, <name><surname>Kiviniemi</surname><given-names>T</given-names></name>, <name><surname>Schlitt</surname><given-names>A</given-names></name>, <name><surname>Rubboli</surname><given-names>A</given-names></name>, <name><surname>Dietrich</surname><given-names>B</given-names></name>, <name><surname>Karjalainen</surname><given-names>P</given-names></name>, <etal>et al</etal>
<article-title>CHADS2, CHA2DS2-VASc and HAS-BLED as predictors of outcome in patients with atrial fibrillation undergoing percutaneous coronary intervention</article-title>. <source>Thromb Res</source>. <year>2014</year>; <volume>133</volume>:<fpage>560</fpage>&#x02013;<lpage>6</lpage>. <pub-id pub-id-type="doi">10.1016/j.thromres.2014.01.007</pub-id>
<pub-id pub-id-type="pmid">24461143</pub-id></mixed-citation></ref><ref id="pone.0227571.ref041"><label>41</label><mixed-citation publication-type="journal"><name><surname>Valgimigli</surname><given-names>M</given-names></name>, <name><surname>Patialiakas</surname><given-names>A</given-names></name>, <name><surname>Thury</surname><given-names>A</given-names></name>, <name><surname>McFadden</surname><given-names>E</given-names></name>, <name><surname>Colangelo</surname><given-names>S</given-names></name>, <name><surname>Campo</surname><given-names>G</given-names></name>, <etal>et al</etal>; <collab>ZEUS Investigators</collab>. <article-title>Zotarolimus-eluting versus bare-metal stents in uncertain drug-eluting stent candidates</article-title>. <source>J Am Coll Cardiol</source>. <year>2015</year>; <volume>65</volume>:<fpage>805</fpage>&#x02013;<lpage>15</lpage>. <pub-id pub-id-type="doi">10.1016/j.jacc.2014.11.053</pub-id>
<pub-id pub-id-type="pmid">25720624</pub-id></mixed-citation></ref><ref id="pone.0227571.ref042"><label>42</label><mixed-citation publication-type="journal"><name><surname>Urban</surname><given-names>P</given-names></name>, <name><surname>Meredith</surname><given-names>IT</given-names></name>, <name><surname>Abizaid</surname><given-names>A</given-names></name>, <name><surname>Pocock</surname><given-names>SJ</given-names></name>, <name><surname>Carri&#x000e9;</surname><given-names>D</given-names></name>, <name><surname>Naber</surname><given-names>C</given-names></name>, <etal>et al</etal>; <collab>LEADERS FREE Investigators</collab>. <article-title>Polymer-free Drug-Coated Coronary Stents in Patients at High Bleeding Risk</article-title>. <source>N Engl J Med</source>. <year>2015</year>; <volume>373</volume>:<fpage>2038</fpage>&#x02013;<lpage>47</lpage>. <pub-id pub-id-type="doi">10.1056/NEJMoa1503943</pub-id>
<pub-id pub-id-type="pmid">26466021</pub-id></mixed-citation></ref><ref id="pone.0227571.ref043"><label>43</label><mixed-citation publication-type="journal"><name><surname>Varenne</surname><given-names>O</given-names></name>, <name><surname>Cook</surname><given-names>S</given-names></name>, <name><surname>Sideris</surname><given-names>G</given-names></name>, <name><surname>Kedev</surname><given-names>S</given-names></name>, <name><surname>Cuisset</surname><given-names>T</given-names></name>, <name><surname>Carri&#x000e9;</surname><given-names>D</given-names></name>, <etal>et al</etal>; <collab>SENIOR investigators</collab>. <article-title>Drug-eluting stents in elderly patients with coronary artery disease (SENIOR): a randomised single-blind trial</article-title>. <source>Lancet</source>. <year>2018</year>; <volume>391</volume>:<fpage>41</fpage>&#x02013;<lpage>50</lpage>. <pub-id pub-id-type="doi">10.1016/S0140-6736(17)32713-7</pub-id>
<pub-id pub-id-type="pmid">29102362</pub-id></mixed-citation></ref><ref id="pone.0227571.ref044"><label>44</label><mixed-citation publication-type="journal"><name><surname>Hart</surname><given-names>RG</given-names></name>, <name><surname>Pearce</surname><given-names>LA</given-names></name>, <name><surname>Aguilar</surname><given-names>MI</given-names></name>. <article-title>Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation</article-title>. <source>Ann Intern Med</source>. <year>2007</year>; <volume>146</volume>:<fpage>857</fpage>&#x02013;<lpage>67</lpage>. <pub-id pub-id-type="doi">10.7326/0003-4819-146-12-200706190-00007</pub-id>
<pub-id pub-id-type="pmid">17577005</pub-id></mixed-citation></ref><ref id="pone.0227571.ref045"><label>45</label><mixed-citation publication-type="journal"><name><surname>Potter</surname><given-names>BJ</given-names></name>, <name><surname>And&#x000f2;</surname><given-names>G</given-names></name>, <name><surname>Cimmino</surname><given-names>G</given-names></name>, <name><surname>Ladeiras-Lopes</surname><given-names>R</given-names></name>, <name><surname>Frikah</surname><given-names>Z</given-names></name>, <name><surname>Chen</surname><given-names>XY</given-names></name>, <etal>et al</etal>
<article-title>Time trends in antithrombotic management of patients with atrial fibrillation treated with coronary stents: Results from TALENT-AF (The internAtionaL stENT&#x02014;Atrial Fibrillation study) multicenter registry</article-title>. <source>Clin Cardiol</source>. <year>2018</year>; <volume>41</volume>:<fpage>470</fpage>&#x02013;<lpage>75</lpage>. <pub-id pub-id-type="doi">10.1002/clc.22898</pub-id>
<pub-id pub-id-type="pmid">29663443</pub-id></mixed-citation></ref><ref id="pone.0227571.ref046"><label>46</label><mixed-citation publication-type="journal"><name><surname>Kikkert</surname><given-names>WJ</given-names></name>, <name><surname>Damman</surname><given-names>P</given-names></name>. <article-title>Optimal duration of dual antiplatelet therapy for coronary artery disease</article-title>. <source>Neth Heart J</source>. <year>2018</year>; <volume>26</volume>:<fpage>321</fpage>&#x02013;<lpage>33</lpage>. <pub-id pub-id-type="doi">10.1007/s12471-018-1113-5</pub-id>
<pub-id pub-id-type="pmid">29713989</pub-id></mixed-citation></ref><ref id="pone.0227571.ref047"><label>47</label><mixed-citation publication-type="journal"><name><surname>Ho</surname><given-names>KW</given-names></name>, <name><surname>Ivanov</surname><given-names>J</given-names></name>, <name><surname>Freixa</surname><given-names>X</given-names></name>, <name><surname>Overgaard</surname><given-names>CB</given-names></name>, <name><surname>Osten</surname><given-names>MD</given-names></name>, <name><surname>Ing</surname><given-names>D</given-names></name>, <etal>et al</etal>
<article-title>Antithrombotic therapy after coronary stenting in patients with nonvalvular atrial fibrillation</article-title>. <source>Can J Cardiol</source>. <year>2013</year>; <volume>29</volume>:<fpage>213</fpage>&#x02013;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1016/j.cjca.2012.08.008</pub-id>
<pub-id pub-id-type="pmid">23089528</pub-id></mixed-citation></ref><ref id="pone.0227571.ref048"><label>48</label><mixed-citation publication-type="journal"><name><surname>De Luca</surname><given-names>G</given-names></name>, <name><surname>Dirksen</surname><given-names>MT</given-names></name>, <name><surname>Spaulding</surname><given-names>C</given-names></name>, <name><surname>Kelb&#x000e6;k</surname><given-names>H</given-names></name>, <name><surname>Schalij</surname><given-names>M</given-names></name>, <name><surname>Thuesen</surname><given-names>L</given-names></name>, <etal>et al</etal>; <collab>DESERT cooperation</collab>. <article-title>Impact of diabetes on long-term outcome after primary angioplasty: insights from the DESERT cooperation</article-title>. <source>Diabetes Care</source>. <year>2013</year>; <volume>36</volume>:<fpage>1020</fpage>&#x02013;<lpage>5</lpage>. <pub-id pub-id-type="doi">10.2337/dc12-1507</pub-id>
<pub-id pub-id-type="pmid">23275351</pub-id></mixed-citation></ref><ref id="pone.0227571.ref049"><label>49</label><mixed-citation publication-type="journal"><name><surname>Shenoy</surname><given-names>C</given-names></name>, <name><surname>Boura</surname><given-names>J</given-names></name>, <name><surname>Orshaw</surname><given-names>P</given-names></name>, <name><surname>Harjai</surname><given-names>KJ</given-names></name>. <article-title>Drug-eluting stents in patients with chronic kidney disease: a prospective registry study</article-title>. <source>PLoS One</source>. <year>2010</year>; <volume>5</volume>:<fpage>e15070</fpage>
<pub-id pub-id-type="doi">10.1371/journal.pone.0015070</pub-id>
<pub-id pub-id-type="pmid">21124771</pub-id></mixed-citation></ref><ref id="pone.0227571.ref050"><label>50</label><mixed-citation publication-type="journal"><name><surname>Zhang</surname><given-names>RY</given-names></name>, <name><surname>Ni</surname><given-names>JW</given-names></name>, <name><surname>Zhang</surname><given-names>JS</given-names></name>, <name><surname>Hu</surname><given-names>J</given-names></name>, <name><surname>Yang</surname><given-names>ZK</given-names></name>, <name><surname>Zhang</surname><given-names>Q</given-names></name>, <etal>et al</etal>
<article-title>Long term clinical outcomes in patients with moderate renal insufficiency undergoing stent based percutaneous coronary intervention</article-title>. <source>Chin Med J (Engl)</source>. <year>2006</year>; <volume>119</volume>:<fpage>1176</fpage>&#x02013;<lpage>81</lpage>. <pub-id pub-id-type="doi">10.1097/00029330-200607020-00007</pub-id>
<pub-id pub-id-type="pmid">16863609</pub-id></mixed-citation></ref><ref id="pone.0227571.ref051"><label>51</label><mixed-citation publication-type="journal"><name><surname>Appleby</surname><given-names>CE</given-names></name>, <name><surname>Ivanov</surname><given-names>J</given-names></name>, <name><surname>Lavi</surname><given-names>S</given-names></name>, <name><surname>Mackie</surname><given-names>K</given-names></name>, <name><surname>Horlick</surname><given-names>EM</given-names></name>, <name><surname>Ing</surname><given-names>D</given-names></name>, <etal>et al</etal>
<article-title>The adverse long-term impact of renal impairment in patients undergoing percutaneous coronary intervention in the drug-eluting stent era</article-title>. <source>Circ Cardiovasc Interv</source>. <year>2009</year>; <volume>2</volume>:<fpage>309</fpage>&#x02013;<lpage>16</lpage>. <pub-id pub-id-type="doi">10.1161/circinterventions.108.828954</pub-id>
<pub-id pub-id-type="pmid">20031733</pub-id></mixed-citation></ref><ref id="pone.0227571.ref052"><label>52</label><mixed-citation publication-type="journal"><name><surname>Chen</surname><given-names>DY</given-names></name>, <name><surname>Mao</surname><given-names>CT</given-names></name>, <name><surname>Tsai</surname><given-names>ML</given-names></name>, <name><surname>Hsieh</surname><given-names>MJ</given-names></name>, <name><surname>Lin</surname><given-names>YS</given-names></name>, <name><surname>Cherng</surname><given-names>WJ</given-names></name>, <etal>et al</etal>
<article-title>Clinical Outcomes of Drug-Eluting Stents vs. Bare-Metal Stents in Acute Myocardial Infarction Patients Under Dialysis&#x02014;A Nationwide Cohort Study</article-title>. <source>Circ J</source>. <year>2016</year>; <volume>80</volume>:<fpage>363</fpage>&#x02013;<lpage>70</lpage>. <pub-id pub-id-type="doi">10.1253/circj.cj-15-0778</pub-id>
<pub-id pub-id-type="pmid">26581755</pub-id></mixed-citation></ref><ref id="pone.0227571.ref053"><label>53</label><mixed-citation publication-type="journal"><name><surname>Iijima</surname><given-names>R</given-names></name>, <name><surname>Araki</surname><given-names>T</given-names></name>, <name><surname>Nagashima</surname><given-names>Y</given-names></name>, <name><surname>Yamazaki</surname><given-names>K</given-names></name>, <name><surname>Utsunomiya</surname><given-names>M</given-names></name>, <name><surname>Hori</surname><given-names>M</given-names></name>, <etal>et al</etal>
<article-title>Incidence and predictors of the late catch-up phenomenon after drug-eluting stent implantation</article-title>. <source>Int J Cardiol</source>. <year>2013</year>; <volume>168</volume>:<fpage>2588</fpage>&#x02013;<lpage>92</lpage>. <pub-id pub-id-type="doi">10.1016/j.ijcard.2013.03.046</pub-id>
<pub-id pub-id-type="pmid">23578895</pub-id></mixed-citation></ref><ref id="pone.0227571.ref054"><label>54</label><mixed-citation publication-type="journal"><name><surname>Tu</surname><given-names>JV</given-names></name>, <name><surname>Bowen</surname><given-names>J</given-names></name>, <name><surname>Chiu</surname><given-names>M</given-names></name>, <name><surname>Ko</surname><given-names>DT</given-names></name>, <name><surname>Austin</surname><given-names>PC</given-names></name>, <name><surname>He</surname><given-names>Y</given-names></name>, <etal>et al</etal>
<article-title>Effectiveness and safety of drug-eluting stents in Ontario</article-title>. <source>N Engl J Med</source>. <year>2007</year>; <volume>357</volume>:<fpage>1393</fpage>&#x02013;<lpage>402</lpage>. <pub-id pub-id-type="doi">10.1056/nejmoa071076</pub-id>
<pub-id pub-id-type="pmid">17914040</pub-id></mixed-citation></ref></ref-list></back><sub-article id="pone.0227571.r001" article-type="aggregated-review-documents"><front-stub><article-id pub-id-type="doi">10.1371/journal.pone.0227571.r001</article-id><title-group><article-title>Decision Letter 0</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Coppola</surname><given-names>Giuseppe</given-names></name><role>Academic Editor</role></contrib></contrib-group><permissions><copyright-statement>&#x000a9; 2020 Giuseppe Coppola</copyright-statement><copyright-year>2020</copyright-year><copyright-holder>Giuseppe Coppola</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p></license></permissions><related-article id="rel-obj001" ext-link-type="doi" xlink:href="10.1371/journal.pone.0227571" related-article-type="reviewed-article"/><custom-meta-group><custom-meta><meta-name>Submission Version</meta-name><meta-value>0</meta-value></custom-meta></custom-meta-group></front-stub><body><p>
<named-content content-type="letter-date">24 Oct 2019</named-content>
</p><p>PONE-D-19-23376</p><p>Drug-eluting versus bare-metal stents for first myocardial infarction in patients with atrial fibrillation: a nationwide population-based cohort study</p><p>PLOS ONE</p><p>Dear Ming-Yow Hung</p><p>Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE&#x02019;s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.</p><p>We would appreciate receiving your revised manuscript by Dec 08 2019 11:59PM. When you are ready to submit your revision, log on to <ext-link ext-link-type="uri" xlink:href="https://www.editorialmanager.com/pone/">https://www.editorialmanager.com/pone/</ext-link> and select the 'Submissions Needing Revision' folder to locate your manuscript file.</p><p>If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter.</p><p>To enhance the reproducibility of your results, we recommend that if applicable you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. For instructions see: <ext-link ext-link-type="uri" xlink:href="http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols">http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols</ext-link></p><p>Please include the following items when submitting your revised manuscript:</p><p><list list-type="bullet"><list-item><p>A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). This letter should be uploaded as separate file and labeled 'Response to Reviewers'.</p></list-item><list-item><p>A marked-up copy of your manuscript that highlights changes made to the original version. This file should be uploaded as separate file and labeled 'Revised Manuscript with Track Changes'.</p></list-item><list-item><p>An unmarked version of your revised paper without tracked changes. This file should be uploaded as separate file and labeled 'Manuscript'.</p></list-item></list></p><p>Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out.</p><p>We look forward to receiving your revised manuscript.</p><p>Kind regards,</p><p>Giuseppe Coppola</p><p>Academic Editor</p><p>PLOS ONE</p><p>Additional Editor Comments (if provided):</p><p>Congratulations for your manuscript and thank you for considering Plos One.</p><p>Your paper underwent two separate revisions. Both reviewers agree about <bold>minor revision</bold>. Their suggestione are well explained in the comments.</p><p>We look forward to see your revised version.</p><p>[Note: HTML markup is below. Please do not edit.]</p><p>Reviewers' comments:</p><p>Reviewer's Responses to Questions</p><p><bold>Comments to the Author</bold></p><p>1. Is the manuscript technically sound, and do the data support the conclusions?</p><p>The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented. </p><p>Reviewer #1: Yes</p><p>Reviewer #2: Yes</p><p>**********</p><p>2. Has the statistical analysis been performed appropriately and rigorously? </p><p>Reviewer #1: Yes</p><p>Reviewer #2: Yes</p><p>**********</p><p>3. Have the authors made all data underlying the findings in their manuscript fully available?</p><p>The <ext-link ext-link-type="uri" xlink:href="http://www.plosone.org/static/policies.action#sharing">PLOS Data policy</ext-link> requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data&#x02014;e.g. participant privacy or use of data from a third party&#x02014;those must be specified.</p><p>Reviewer #1: Yes</p><p>Reviewer #2: Yes</p><p>**********</p><p>4. Is the manuscript presented in an intelligible fashion and written in standard English?</p><p>PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.</p><p>Reviewer #1: Yes</p><p>Reviewer #2: Yes</p><p>**********</p><p>5. Review Comments to the Author</p><p>Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)</p><p>Reviewer #1: Introduction: the quoted guidelines are outdated; the Authors should review the entire section according to the last iteration of the ACC/AHA and ESC guidelines, both about type of stent and about antithrombotic regimen; for completeness, they should put their study (enrolling started more than 10 years ago) in context to the evidences of that era.</p><p>Discussion: the Authors should discuss their study in the light of three major RCTs comparing DES and BMS for patients considered at high risk of bleeding, such as ZEUS (Valgimigli et al.), LEADES-FREE (Urban et al.) and SENIOR (Varenne et al.) , and also of observational studies reporting management of patients with AF and coronary stents (see Potter at al, Clin Cardiol. 2018 Apr;41(4):470-475. doi: 10.1002/clc.22898).</p><p>Reviewer #2: The authors deals with a very important issue, that is to say use of antiplatelet therapy in patients already on anticoagulants for AF. The paper is well written and the statistical analysis solid, thus the conclusions are reliable. I only have some minor questions:</p><p>1. In Table 1 patients are divided in categories according to their CHA2DS-VASc score, and score 1 and 2 are included in the some category. In my opinion pts with a CHA2DS2-VASc score = 1 should be separated from pts with a score of 2, because they could even not receive an anticoagulant</p><p>2. How can pts have a score of 0, if they have at least cardiovascular disease?</p><p>3. What about pts not on warfarin? Only about 9% of pts are on warfarin: and the other ones? Are they on DOAC? Which type at which dose: full or reduced?</p><p>**********</p><p>6. PLOS authors have the option to publish the peer review history of their article (<ext-link ext-link-type="uri" xlink:href="https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history">what does this mean?</ext-link>). If published, this will include your full peer review and any attached files.</p><p>If you choose &#x0201c;no&#x0201d;, your identity will remain anonymous but your review may still be made public.</p><p><bold>Do you want your identity to be public for this peer review?</bold> For information about this choice, including consent withdrawal, please see our <ext-link ext-link-type="uri" xlink:href="https://www.plos.org/privacy-policy">Privacy Policy</ext-link>.</p><p>Reviewer #1: No</p><p>Reviewer #2: Yes: Giosue Mascioli, MD; FESC, FEHRA, FAIAC</p><p>[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files to be viewed.]</p><p>While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <ext-link ext-link-type="uri" xlink:href="https://pacev2.apexcovantage.com/">https://pacev2.apexcovantage.com/</ext-link>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <email>figures@plos.org</email>. Please note that Supporting Information files do not need this step.</p></body></sub-article><sub-article id="pone.0227571.r002" article-type="author-comment"><front-stub><article-id pub-id-type="doi">10.1371/journal.pone.0227571.r002</article-id><title-group><article-title>Author response to Decision Letter 0</article-title></title-group><related-article id="rel-obj002" ext-link-type="doi" xlink:href="10.1371/journal.pone.0227571" related-article-type="editor-report"/><custom-meta-group><custom-meta><meta-name>Submission Version</meta-name><meta-value>1</meta-value></custom-meta></custom-meta-group></front-stub><body><p>
<named-content content-type="author-response-date">15 Dec 2019</named-content>
</p><p>&#x0fffd;Response to reviewers</p><p> We would like to extend our thanks to the reviewers for the constructive comments regarding our manuscript, entitled, &#x0201c;Drug-eluting versus bare-metal stents for first myocardial infarction in patients with atrial fibrillation: A nationwide population-based cohort study&#x0201d; (Manuscript number PONE-D-19-23376). We have revised the manuscript point by point in accordance with the reviewer&#x02019;s suggestions, as indicated by the itemized responses below.</p><p>Reviewer #1:</p><p>1. Introduction: the quoted guidelines are outdated; the Authors should review the entire section according to the last iteration of the ACC/AHA and ESC guidelines, both about type of stent and about antithrombotic regimen; for completeness, they should put their study (enrolling started more than 10 years ago) in context to the evidences of that era.</p><p>Response to reviewer: </p><p>We appreciate the reviewer&#x02019;s comments. We have reviewed the entire section according to the last iteration of the ACC/AHA and ESC guidelines, both about type of stent and about antithrombotic regimen. We also have described the development of evidence over time through our study period. Guidelines and reviews of the literature have been added to the &#x0201c;Introduction&#x0201d; sections in this revised manuscript (Page 3, lines 65-68, Page 4, lines 69-84 and 89-91 and Page 5, lines 92, 94 and 97-101). Thank you for your comment.</p><p>2. Discussion: the Authors should discuss their study in the light of three major RCTs comparing DES and BMS for patients considered at high risk of bleeding, such as ZEUS (Valgimigli et al.), LEADES-FREE (Urban et al.) and SENIOR (Varenne et al.), and also of observational studies reporting management of patients with AF and coronary stents (see Potter at al, Clin Cardiol. 2018 Apr;41(4):470-475. doi: 10.1002/clc.22898).</p><p>Response to reviewer: </p><p>We appreciate the reviewer&#x02019;s comments. As the reviewer suggested, we have added the detailed reviews of the 3 major RCTs and 1 observational study regarding the management of patients with AF and coronary stents to the &#x0201c;Discussion&#x0201d; section in this revised manuscript (Page 20, lines 334-338, Page 21, lines 359-370 and Page 22, lines 371-380). Thank you for your comment.</p><p>Reviewer #2:</p><p>1. In Table 1 patients are divided in categories according to their CHA2DS-VASc score, and score 1 and 2 are included in the same category. In my opinion pts with a CHA2DS2-VASc score = 1 should be separated from pts with a score of 2, because they could even not receive an anticoagulant.</p><p>Response to reviewer: </p><p>We appreciate the reviewer&#x02019;s comments. We have modified and improved the data presentation of the subgroup analysis in Table 1 and Figure 3. Thank you for your comment.</p><p>2. How can pts have a score of 0, if they have at least cardiovascular disease?</p><p>Response to reviewer: </p><p>We appreciate the reviewer&#x02019;s comments. While all patients included in this study should have at least a CHA2DS2-VASc score of 1, the reason why some patients had a score of 0 is that we defined the coronary artery disease by using ICD-9-CM diagnosis prior to the index admission. We apologize for this coding error, and have redefined the coronary artery disease using ICD-9-CM diagnosis &#x0201c;during&#x0201d; or prior to the index admission. We have modified and improved the data presentation of the subgroup analysis in Table 1 and Figure 3. Thanks for your reminder and comment.</p><p>3. What about pts not on warfarin? Only about 9% of pts are on warfarin: and the other ones? Are they on DOAC? Which type at which dose: full or reduced?</p><p>Response to reviewer: </p><p>We appreciate the reviewer&#x02019;s comments. The available Taiwan NHIRD in our study included only inpatient claims data with no information of medications from the outpatient claims data and pharmacy claims data. Furthermore, although the DOAC has been covered by Taiwan&#x02019;s NHI system since 2012, our study period was from 1997 to 2011. Therefore, the use of oral anticoagulants was infrequent in our study. We have added the above statement to the limitation section in this revised manuscript (Page 25, lines 442-446). Thank you for your comment.</p><p>&#x0fffd;List of changes</p><p>The page and reference numbers in this list are those in the revised and re-submitted manuscript.</p><p>All of the above revisions are highlighted with underlines and red color in the revised manuscript. Thank you very much for your recommendations.</p><p>1. Page 3, lines 65-68, Page 4, lines 69-84 and 89-91 and Page 5, lines 92, 94 and 97-101: As the reviewer suggested, guidelines and reviews of the literature were added.</p><p>2. Page 20, lines 334-338, Page 21, lines 359-370 and Page 22, lines 371-380: As the reviewer suggested, the detailed reviews of the 3 major RCTs and 1 observational study regarding the management of patients with AF and coronary stents were added. </p><p>3. Page 25, lines 442-446: As the reviewer suggested, the reasons why the use of oral anticoagulants was infrequent in our study were added.</p><p>4. Page 26, line 479: The author contribution for revising this manuscript was added.</p><p>5. Page 28, 29, 30, 31, 33 and 35: The reference number was sequentially changed as follows: 11 to 9, 8 to 10, 9 to 17, 10 to 18, 12 to 21, 13 to 22, 14 to 23, 15 to 24, 16 to 25, 17 to 26, 18 to 27, 19 to 28, 20 to 29, 21 to 30, 22 to 31, 23 to 32, 24 to 34, 25 to 35, 26 to 36, 27 to 37, 28 to 38, 29 to 39, 30 to 40, 31 to 46, 32 to 47, 33 to 48, 34 to 49, 35 to 50, 36 to 51, 37 to 52, 38 to 53, 39 to 54.</p><p>6. Page 28: One reference (J Am Coll Cardiol. 2006; 48:854-906.) was added as reference 8.</p><p>7. Pages 29-30: 6 references (Lancet. 2013; 381:1107-15.; Thromb Res. 2015; 135:26-30.; Circulation. 2019; 140:e125-e151.; N Engl J Med. 2016; 375:2423-34.; N Engl J Med. 2017; 377:1513-24.; Circulation. 2018; 138:527-36.) were added as reference 11-16.</p><p>8. Pages 30-31: 2 references (J Am Coll Cardiol. 2011; 58:e44-122.; Circ Cardiovasc Interv. 2016; 9. pii: e004395.) were added as reference 19, 20.</p><p>9. Page 33: One reference (Circulation. 2008; 117:261-95.) was added as reference 33.</p><p>10. Pages 35: 5 references (J Am Coll Cardiol. 2015; 65:805-15.; N Engl J Med. 2015; 373:2038-47.; Lancet. 2018; 391:41-50.; Ann Intern Med. 2007; 146:857-67.; Clin Cardiol. 2018; 41:470-75.) were added as reference 41-45.</p><supplementary-material content-type="local-data" id="pone.0227571.s002"><label>Attachment</label><caption><p>Submitted filename: <named-content content-type="submitted-filename">20191215 Response to Reviewers_R2.doc</named-content></p></caption><media xlink:href="pone.0227571.s002.doc"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></body></sub-article><sub-article id="pone.0227571.r003" article-type="editor-report"><front-stub><article-id pub-id-type="doi">10.1371/journal.pone.0227571.r003</article-id><title-group><article-title>Decision Letter 1</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Coppola</surname><given-names>Giuseppe</given-names></name><role>Academic Editor</role></contrib></contrib-group><permissions><copyright-statement>&#x000a9; 2020 Giuseppe Coppola</copyright-statement><copyright-year>2020</copyright-year><copyright-holder>Giuseppe Coppola</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p></license></permissions><related-article id="rel-obj003" ext-link-type="doi" xlink:href="10.1371/journal.pone.0227571" related-article-type="reviewed-article"/><custom-meta-group><custom-meta><meta-name>Submission Version</meta-name><meta-value>1</meta-value></custom-meta></custom-meta-group></front-stub><body><p>
<named-content content-type="letter-date">23 Dec 2019</named-content>
</p><p>Drug-eluting versus bare-metal stents for first myocardial infarction in patients with atrial fibrillation: a nationwide population-based cohort study</p><p>PONE-D-19-23376R1</p><p>Dear Dr. Ming-Yow Hung,</p><p>We are pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it complies with all outstanding technical requirements.</p><p>Within one week, you will receive an e-mail containing information on the amendments required prior to publication. When all required modifications have been addressed, you will receive a formal acceptance letter and your manuscript will proceed to our production department and be scheduled for publication.</p><p>Shortly after the formal acceptance letter is sent, an invoice for payment will follow. To ensure an efficient production and billing process, please log into Editorial Manager at <ext-link ext-link-type="uri" xlink:href="https://www.editorialmanager.com/pone/">https://www.editorialmanager.com/pone/</ext-link>, click the "Update My Information" link at the top of the page, and update your user information. If you have any billing related questions, please contact our Author Billing department directly at <email>authorbilling@plos.org</email>.</p><p>If your institution or institutions have a press office, please notify them about your upcoming paper to enable them to help maximize its impact. If they will be preparing press materials for this manuscript, you must inform our press team as soon as possible and no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact <email>onepress@plos.org</email>.</p><p>With kind regards,</p><p>Giuseppe Coppola</p><p>Academic Editor</p><p>PLOS ONE</p></body></sub-article><sub-article id="pone.0227571.r004" article-type="editor-report"><front-stub><article-id pub-id-type="doi">10.1371/journal.pone.0227571.r004</article-id><title-group><article-title>Acceptance letter</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Coppola</surname><given-names>Giuseppe</given-names></name><role>Academic Editor</role></contrib></contrib-group><permissions><copyright-statement>&#x000a9; 2020 Giuseppe Coppola</copyright-statement><copyright-year>2020</copyright-year><copyright-holder>Giuseppe Coppola</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p></license></permissions><related-article id="rel-obj004" ext-link-type="doi" xlink:href="10.1371/journal.pone.0227571" related-article-type="reviewed-article"/></front-stub><body><p>
<named-content content-type="letter-date">31 Dec 2019</named-content>
</p><p>PONE-D-19-23376R1 </p><p>Drug-eluting versus bare-metal stents for first myocardial infarction in patients with atrial fibrillation: a nationwide population-based cohort study </p><p>Dear Dr. Hung:</p><p>I am pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department. </p><p>If your institution or institutions have a press office, please notify them about your upcoming paper at this point, to enable them to help maximize its impact. If they will be preparing press materials for this manuscript, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact <email>onepress@plos.org</email>.</p><p>For any other questions or concerns, please email <email>plosone@plos.org</email>. </p><p>Thank you for submitting your work to PLOS ONE.</p><p>With kind regards,</p><p>PLOS ONE Editorial Office Staff</p><p>on behalf of</p><p>Dr. Giuseppe Coppola </p><p>Academic Editor</p><p>PLOS ONE</p></body></sub-article></article>